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The incidence of cancer is highly dependent on age.  The hypothesis of this 
thesis was that aging may alter the efficacy of dietary chemoprevention.  This 
hypothesis was tested by evaluating the effect of age on inhibition of colonic aberrant 
crypt foci (ACF) by dietary curcumin.  Three different ages of male F344 rats were 
fed either the control diet or diet containing 0.6% curcumin and given injections of a 
colon carcinogen, azoxymethane (AOM).  Curcumin reduced the number of colonic 
ACF in young and old, but not middle-aged rats.  Resistance of middle-aged rats to 
colonic chemoprevention by curcumin seems to be due to age-related differences in 
colon carcinogensis rather than curcumin metabolism.  Liver cyclooxygenase-2 
mRNA expression, measured as an indicator of biological activity of curcumin, was 
similarly affected by curcumin regardless of ages.  Also, curcumin similarly affected 
arachidonic acid metabolism, which is regarded as one of chemopreventive 
mechanisms of curcumin, in the colon of young and middle-aged rats.   
The involvement of apoptosis was investigated as a potential mechanism 
responsible for age-related differences in curcumin chemoprevention.  A time course 
study of colonic apoptosis following AOM injections demonstrated that older animals 
were more susceptible to AOM-induced apoptosis.  The effect of aging on 
curcumin-induced apoptosis in the colon was evaluated at 0, 8, and 16 hours after 
AOM injection.  Curcumin increased both basal and AOM-induced apoptosis in 
young and old but not in middle-aged rats.  Activation of caspase-9 only in young 
rats fed curcumin indicates that curcumin-induced apoptotic pathway is mediated by 
mitochondria in young but not in old.  AOM may also induce apoptosis by a 
mitochondrial-independent pathway.   
In conclusion, these studies support the hypothesis that aging modulates 
colonic chemoprevention by curcumin.  This dissertation represents the first 
documentation of an age-related difference in efficacy of dietary chemoprevention.  
The differential response to curcumin-induced apoptosis is proposed as a mechanism.  
Further study is needed to confirm whether this phenomenon occurs in humans and 
contributes to the lack of agreement between efficacy of dietary chemoprevention in 
preclinical studies with young animals and clinical studies with adult humans. 
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Chapter 1. Literature Review 
 
1.1 Cancer: a disease of the elderly 
Cancer is often characterized as a multi-step process, including initiation, 
promotion and progression (1).  Exposure to carcinogens induces mutations either 
directly or through formation of DNA adducts.  DNA adducts can cause mutations 
and mutations left without repair can be permanently fixed by DNA replication.  If 
this mutation occurs at genes that regulate cell growth and sites critical for protein 
function, cancer can be initiated.  However, cancer initiation is not enough to 
develop tumors.  Promotion to tumors involves selective growth of initiated cancer 
cells.  This step is mediated by promoting factors such as inflammatory responses 
and hormones.  As the tumor grows, cancer cells acquire more mutations, lose 
cellular differentiation, and tend to metastasize.  The acquisition of the ability to 
metastasize results in progression to metastatic tumors. 
The incidence of cancer is highly dependent on age (2).  In humans, cancer 
incidence exponentially increases with age from age 40 to 80 (3).  More notably, the 
majority of cancers in the older ages are derived from epithelial cells (3).  Although 
it is unclear how the aging process is involved in carcinogenesis, there are several 
suggested mechanisms to explain the marked rise of cancer incidence in the aged.  
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Sequential accumulation of somatic mutations over a lifetime has long been 
considered to contribute age dependence in cancer incidence.  This view has recently 
been reinforced in the reviews by Peto (4) and Dix (5).  According to this hypothesis, 
we are continuously exposed to various endogenous and exogenous DNA damaging 
agents through the lifetime.  The high prevalence of cancer in the older subjects 
simply reflects a more prolonged exposure to carcinogens.  Cancer is a disease of 
genes as described above.  Also, somatic mutation due to oxidative damage, an 
endogenous carcinogen, increases with age (6).  However, frequent mutations are 
also observed in normal appearing tissues (2).  Moreover, this hypothesis may not be 
enough to explain why epithelial cell driven cancers are predominant in older 
individuals (3).  Therefore, it is unlikely that overload of somatic mutation alone in 
the aged is sufficient to drive cancer. 
There is increasing evidence that the cellular microenvironment is a potent 
factor to determine suppression or promotion of malignant phenotype (2, 3, 7).  
Successive studies of McCullough et al. (8-10) showed that the development of 
tumors from epithelial cancer cells was affected by changes in tissue 
microenvironment and that the aging process causes such alterations in the tissue 
environment.  In their studies, intrahepatic transplantation of liver neoplastic 
epithelial cells rapidly produces tumors at the sites of inoculation both in young and 
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old rats.  However, tumors at the transplantation site in young rats eventually regress, 
whereas in older rats, tumors grow progressively (8).  McCullough et al. also found 
that liver neoplastic epithelial cells transplanted in extrahepatic sites did not regress, 
even in young animals (9).  Cells transplanted to the liver reside as differentiated 
hepatocytes.  Upon withdrawal from the liver, neoplastic epithelial cells revert to an 
undifferentiated and malignant phenotype (10), indicating the importance of 
environmental signals to suppress malignancy.  Krtolica et al. (11) also reported that 
senescent cells stimulate growth of premalignant cells but not normal cells in culture.  
Senescent fibroblasts induce premaligant and malignant cells to form tumors in vivo 
(11).  These findings suggest that the microenvironment can be a powerful 
modulator of tumor development from initiated cancer cells.  More importantly, the 
aging process may modulate tissue environment, promoting cancer cells to develop 
malignant tumors.  Thus, the age-related increase in cancer results from the interplay 
of both accumulation of mutations and alteration of tissue milieu to promote tumor 
development with age, as suggested by Krtolica et al. (2, 11).   
 
1.2 Diet and colon cancer  
Colorectal cancer is a leading neoplastic disease that affects both men and 
women in high frequency in Western countries, including the United States (4).  
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Cancer statistics for 2005 demonstrate that colon cancer is the third most common 
cancer both in men and women (12).  About 104,950 new cases of colon cancer are 
expected to be diagnosed and about 56,290 men and women together are expected to 
die of cancer of colon and rectum in 2005 (12).   
Cancer risk is associated with both inherent factors such as mutations and 
environmental factors including diet, tobacco use, and physical activity (4).  
Interestingly, colon cancer risk is closely related with dietary factors.  For example, 
red meat consumption appears to increase the risk of colorectal cancer (13).  There is 
converging agreement that heme may be responsible for the increase of colon cancer 
by high consumption of red meat (14, 15).  Several case-control studies (16, 17) 
showed that colorectal cancer risk was positively correlated with high consumption of 
well-done meat probably due to heterocyclic amines (HCA) produced by pyrrolysis of 
meats when cooked at high temperature (18).  In addition, this relationship was 
further enhanced when genetic polymorphism of HCA-metabolizing enzymes was 
considered (16).  Dietary fat has been considered to increase cancers related with 
Western lifestyle, including colorectal cancer (19).  However, not only amount of 
consumption but also the fatty acid composition appears to contribute to the increase 
of colon cancer (20).  Generally, n-3 polyunsaturated fatty acids are thought to 
protect against colorectal cancer (21, 22) whereas n-6 polyunsaturated fatty acids 
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appear to promote colon carcinogenesis (21, 23).  
On the other hand, some nutrients and phytochemicals show a preventive 
effect on colon cancer.  Epidemiological studies showed that high consumption of 
fruits and vegetables is negatively associated with colon cancer risk.  As a result, 
plant foods and compounds derived from plants have been widely investigated in 
relation with prevention of colon cancer (24-27).  Several prospective studies 
showed that high calcium consumption has a negative relationship with risk of colon 
cancer (28, 29).  Sesink et al. (14) suggested that dietary calcium inhibits colon 
carcinogenesis by inhibiting the hyperproliferative effect of dietary heme.  It is 
generally considered that dietary intake of folate is inversely related with colorectal 
cancer risk due to its role in one carbon transfer in DNA synthesis (30, 31).  
Polymorphism in the methylenetetrahdrofolate reductase gene, which causes DNA 
hypomethylation, seems to modulate colorectal cancer risk when folate status is low 
(30, 31), showing a diet-gene interaction in colon carcinogenesis.  A diet-diet 
interaction in colon carcinogenesis also has been reported by Lupton and colleagues 
(32).  Their study suggested that fish oil may be protective against experimentally-
induced colon carcinogenesis by enhancing apoptosis when compared to corn oil diets, 
but this depended on the dietary fiber included in the diet (33).  Therefore, as we 
further understand diet-gene interactions as well as diet-diet interactions, it is 
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becoming more apparent that dietary components greatly impact colon carcinogenesis.  
 
1.3 Colon cancer prevention study in animal models 
Reliable preclinical models are critical in understanding etiology, 
development, and control of human diseases including colorectal cancer (34).  In fact, 
animal model studies of colon cancer have contributed considerably to our 
understanding of colon carcinogensis and evaluation of nutritional and 
chemopreventive agents for the prevention of colon cancer.  The APCmin/+ mouse 
model and the azoxymethane (AOM) rat models are the main animal models used to 
study development and prevention of colon cancer (34). 
Reddy and colleagues (34) have largely contributed to establishing the AOM 
rat model.  Using this model, they have tested many potential chemopreventive 
agents.  AOM is an alkylating agent.  After AOM is administered, methyl groups of 
AOM are hydroxylated to azoxymethanol (MAM), probably by CYP2E1 and other 
cytochrome P450 enzymes (35).  MAM can be further oxidized in the liver and 
extrahepatic organs, including the colon, producing methylazoxyformaldehyde that 
produces the highly electrophilic methyldiazonium ion.  Methyldiazonium ions 
eventually methylate DNA and form DNA adducts prone to mutation (35).  Other 
alkylating agents including 1,2-dimethylhydrazine, a precursor of AOM, also have 
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been used to induce colon cancer in specific strains of rats (36-39).  Direct acting 
carcinogens, such as methylnitrosourea or N-methyl-N’-nitro-N-nitrosoguanidine are 
used for chemically-induced animal models (40, 41).  Heterocyclic amines, like 2-
amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP), is another class of 
chemicals that has been used as a colon cancer inducing agent.  In contrast to AOM, 
PhIP is present in our daily foods (42, 43).  It has been argued that PhIP-induced 
colon tumor model is a more appropriate model for mimicking human colon cancer 
studies (43).  However, AOM has been extensively used by many investigators as it 
is less expensive, more potent and more convenient to use (34).   
If AOM is given weekly twice subcutaneous (s.c.) injection at the dose of 15 
mg/kg body weight, the first visible colon tumors can be endoscopically detected 15 
weeks after the treatment and the mean latency period of such tumors is about 20 
weeks (44).  It has been demonstrated that AOM-induced tumors share many 
morphologic and histopathologic characteristics with human tumors (34).  In 
addition, the biological behavior of AOM-induced rat colon carcinomas is similar to 
that of human colon carcinomas (34).  AOM-induced carcinomas metastasize to 
regional lymph nodes and the liver.  Also, as in human colon cancer, both adenomas 
and adenocarcinomas occur in the AOM-rat model (34).  Genetic mutational changes 
in AOM-induced colon have been largely studied by Takahashi and colleagues (45-
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48).  In AOM-induced colon tumors, mutations in K-Ras gene are as frequent as in 
human colorectal tumors (45, 48).  However, in contrast to human tumors, Apc gene 
mutations are rarely observed in AOM-induced tumors (49).  Apc mutations have 
been found in patients with familial adenomatous polyposis (FAP) who have germline 
mutations in one of the Apc alleles as well as in sporadic colon cancer (50, 51).  The 
protein products of mutant Apc genes are defective in their ability to stimulate 
degradation, resulting in stabilization and accumulation of β-catenin in plasma (52).  
Interestingly, Takahashi et al. (46, 47, 53) reported that β-catenin genes are frequently 
mutated in AOM-induced colon tumors, suggesting that similar pathways are involved 
in both human and AOM-induced rat colon carcinogenesis.  
The multiple intestinal neoplasia (Min) mouse was first identified by Moser 
et al. (54).  This Min mouse has mutated Apc genes in heterozygous forms and 
mimics the rapid development of adenomatous polyps as shown in humans with FAP 
(55).  After the discovery of the Min mouse with truncated Apc in position 850, other 
genetically modified models have been developed such as mice with mutations in 
different location of the Apc gene or other cancer related genes like Msh2 and Mlh1 
(50).  This Min mouse model develops a large number of tumors within short time.  
Min mice on a C57BL/6J background develop an average of more than 50 tumors 
within 90 days of birth (55).  However, the major drawback of this mutant model is 
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that tumors occur predominantly in the small intestine, not in the colon (50).  
Moreover, most tumors in the Min mouse are adenomatous whereas adenocarcinomas, 
more invasive tumors, are seldom observed (34).  In addition, the K-Ras mutations 
observed in many human tumors were not detected in Min mice tumors (50).  In 
spite of these drawbacks of the Min mouse as a model of human colon cancer, this 
model has provided a shorter assay time to evaluate tumors and has made a 
contribution to the understanding of the colon cancer process and prevention by diets 
and chemopreventive agents.  
Corpet and Pierre (50) recently reported in their review that there is a 
correlation, in general, between the efficacy of diets or chemopreventive agents in the 
Min mouse model and the AOM rat model.  They concluded that there is a close 
agreement between the results observed in the colons of the AOM rat model and in 
the small intestine of the Min mouse model.  They also examined the relationship of 
animal studies with human trials.  When they compared the results of colon tumor 
incidence in AOM-treated rats or polyp number in Min mice to the recurrence of 
colonic adenomatous polyps in human trials, many promising chemopreventive agents 
which strongly and consistently suppressed colon carcinogenesis in animal models 
showed at best modest effect in inhibiting colon carcinogenesis in humans.  There 
are differences in end points, cancer incidence vs. recurrence of polyps, and other 
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limiting factors in human studies such as compliance to the chemopreventive agents 
and errors in sample selection as addressed by Corpet and Pierre (50).  Also, 
differences of pharmacokinetics of chemopreventive agents caused by species 
difference may contribute to the efficacy of agents in inhibiting colon cancer.  
However, one of main differences that have not been considered may be the age of the 
target group.  Human intervention trials with chemopreventive agents target middle 
to older adults, whereas preclinical studies have been exclusively conducted with 
young animals.  As described earlier, aging is perhaps the most potent carcinogen 
which drives cancer including colorectal cancer, and tissue milieu altered with age 
appears to promote tumor development.  Consequently, the effect of age on 
chemoprevention should be considered in interpretation of preclinical results to 
human trials. 
 
1.4 Aberrant crypt foci as a biomarker of colon cancer 
To investigate the effects of dietary factors on colon cancer development in 
animal models, evaluation of the number, size, and the extent of aggressiveness of 
tumors are used.  Min mice, which rapidly develop tumors, rarely live more than 150 
days of age on the c57BL/6J background due to pathologies other than colon cancer 
including anemia and intestinal blockage (54).  As a result, this model cannot be 
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used in aging studies.  However, a long period of time is required to develop colon 
tumors when tumors are induced with chemical agents as in the AOM rat model.  
Consequently, surrogate end point biomarkers have been sought to predict tumor 
incidence.  Aberrant crypt foci (ACF) have been regarded as precancerous lesions 
and have been widely used as a biomarker of colon cancer in many studies (56).   
Bird (57) first identified ACF from the colon mucosa of mice treated with 
AOM and defined them as crypts that have altered luminal opening; exhibit thickened 
epithelia; and are larger than adjacent normal crypts.  ACF are observed in rodents 
administered colon chemical carcinogens but are not present in the colon of untreated 
animals (56).  However, there is a report (58) that ACF were observed in old 
untreated rats, but not in young.  Later, Pretlow et al. (59) also found the presence of 
such lesions in the colon of patients with colon cancer.  Identification of ACF lead to 
a number of studies to evaluate molecular, morphological, and growth features of 
ACF and to assess their nature as precursor lesions of colon cancer (56).  The 
number and growth of ACF are enhanced or suppressed in response to known 
promoters or inhibitors of colon cancer (60, 61).  It has been reported that ACF 
harbor mutations in K-Ras genes both in rodent and human colons as often observed 
in colon tumors (46).  Increases of inducible nitric oxide synthase have also been 
observed in AOM-induced ACF and in human colon tumors (47).  Hyperplastic ACF, 
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which are less advanced, have a higher tendency to harbor K-Ras mutations and no β-
catenin mutations whereas dysplastic ACF, which are more advanced, showed altered 
cellular localization of β-catenin (46).  Hao et al. (21) also reported altered β-catenin 
expression in human colonic aberrant crypt foci. 
Important findings in interpreting ACF data were made by a limited 
sequential analysis of the number and growth of ACF prior to and at the time of tumor 
appearance.  Magnuson et al. (62) showed that total number of ACF was decreased 
not increased in rat colons by feeding of diet containing 0.2% cholic acid, a known 
colon cancer promoter.  However, when the number of ACF were examined 
separately by crypt multiplicity (number of crypt per focus), ACF with large 
multiplicity were increased by cholic acid diet over time whereas ACF with small 
multiplicity decreased as duration of ACF increased, suggesting selective stimulation 
of ACF by cholic acid.  Recently, Papanilolaou et al. (63) also suggested that large 
ACF are more relevant to predict tumor outcome.  They sequentially analyzed ACF 
and tumors in three strains of mice differing in susceptibility to AOM in developing 
colon cancer.  In their study, almost no differences were found among different 
strains of mice in total number of ACF whereas large ACF (5 and over crypts/focus) 
were correlated with tumor incidence and susceptibility to AOM-induced colon 
tumors.  Moreover, morphological analysis of ACF showed that most susceptible 
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mice had the highest percentage of dysplastic ACF (the more advanced forms), 
followed by the relatively susceptible strain, indicating that the difference in 
susceptibility may be due to the lack of progression of smaller ACF in the resistant 
mice (63).   
There is a general agreement that ACF are preneoplastic lesions of colon 
cancer.  The model of genetic changes associated with human colorectal 
tumorigenesis (64, 65) supports hypothesis that ACF are precursor lesions and that 
carcinomas arise from preexisting dysplastic ACF.  In this model, Apc mutations 
initiate the neoplastic process and develop into numerous dysplastic ACF.  Some, but 
not all, ACF progress to adenoma as they acquire K-Ras mutations and develop to 
carcinoma as they acquire additional mutations including mutations in p53 (65, 66).  
However, it should be noted that the majority of ACF will not develop into colon 
tumors and that ACF are heterogeneous at the morphological and molecular levels.  
Therefore, ACF with large multiplicity or advanced ACF should be considered 
predictive of tumor incidence when ACF are utilized as a biomarker of colon cancer 
although evaluation of tumors is the best way to investigate the effect of dietary 





1.5 Curcumin and colon cancer prevention 
Many compounds of plant origin have been studied in relation to their 
biological activity.  Curcumin is one of the compounds that have been extensively 
studied in a broad spectrum of biological activity including antioxidative activity, 
lipid and cholesterol lowering activity and anti-inflammatory activity (67-69).  Many 
studies also showed potential chemopreventive activity of curcumin in many different 
types of cancer such as skin, colon, breast, prostate, lung and liver (70-75).  Some 
studies also indicated potential combinational use of curcumin to improve efficacy of 
other cancer treatments as shown in adjunct use with TRAIL-mediated 
immunotherapy (76), and to reduce treatment-induced toxicity as observed in 
radioprotective effect of curcumin when curcumin is given before or after γ-ray 
irradiation (77). 
Curcumin is a polyphenolic compound imparting the yellow color in the spice 
turmeric (78).  Turmeric, powdered rhizome of Curcuma longa Linn., has been 
extensively used for flavor and color in food preparation and also for treatment of 
inflammatory conditions and other diseases in East Asia (78).  In India, one of the 
countries that consume high amount of curcumin in their diet, the rates of colorectal, 
prostate, and lung cancer are among the lowest in the world (79).  During its long 
history of usage in diet, almost no toxicity of curcumin has been reported.  A recent 
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pharmacological study of curcumin also showed that there is no dose-limiting toxicity 
at doses between 450 and 3,600 mg per day for four months in colon cancer patients 
(80).  At least two phase I curcumin clinical trials were completed or are ongoing (80, 
81) and curcumin is in a phase II clinical trial for the prevention of colorectal cancer. 
Many studies using human cell lines and animal models have demonstrated 
chemopreventive activity of curcumin against colon cancer.  Feeding 0.2% curcumin 
to F344 rats inhibited both AOM-induced ACF formation (82) and tumor 
development (71, 72).  Curcumin also decreased incidence of intestinal tumors in the 
Min mouse model (27, 42).  Inhibition of cell growth by curcumin was observed in 
different colon cancer cell lines with different genotypes and phenotypes including 
HT-29, HCT116, SW620, and SW480 (83-85).  These studies with preclinical 
models also suggested potential chemopreventive mechanisms through which 
curcumin acts.   
Earlier studies investigated anti-inflammatory activity of curcumin in relation 
with mechanisms of colon cancer prevention.  Cyclooxygenases (COX) are enzymes 
that mediate inflammatory process, catalyzing conversion of arachidonic acids into 
prostaglandins (86).  Two isoforms of COX are known, COX-1 and COX-2.  COX-
1 is constitutively expressed, maintaining normal physiological function.  In contrast, 
COX-2 is induced by cytokines, mitogens and tumor promoters.  Many studies have 
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reported that COX-2 is highly expressed in colon tumors (87-89) and inhibition of 
COX-2 is related with colon cancer prevention (90).  Curcumin inhibited 
phospholipases, responsible for generation of arachidonic acid and formation of 
prostaglandin E2 both in colonic mucosa and colon tumors (71).  Goel (91) also 
reported that curcumin inhibited COX-2 expression at mRNA and protein levels but 
did not affect COX-1 expression in HT29 cells.   
Curcumin is also known to inhibit activation of nuclear transcription factor 
κB (NF-κB) by inhibiting I-κB kinase (IKK) activity (83).  NF-kB is present in the 
cytoplasm as an inactive form bound with its endogenous inhibitor, IκBα.  
Following stimulation by cytokines, IκBα is phosphorylated by successive kinases 
including NF-κB inducing kinase (NIK) and IKK and undergoes rapid degradation, 
resulting in activation of NF-κB and triggering gene transcription related with cell 
survival (92, 93).  In addition, studies with cell lines derived from colon cancer have 
showed that curcumin modulates cell signaling pathways, inhibiting cell proliferation 
as well as inducing apoptosis (92, 94-96).  
 
1.6 Induction of apoptosis: one of chemopreventive mechanisms of curcumin  
Apoptosis, programmed cell death, is the process by which cellular proteins 
and DNA decompose in an orderly manner.  Cells are subsequently taken up by 
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phagocytosis.  In mitotic tissues such as the colon where cells continuously 
proliferate, cell number is maintained by apoptosis in coordination with cell 
proliferation (97).  Apoptosis also plays an important role in removing unwanted 
cells caused by severe DNA damage which otherwise may develop into a neoplasm, 
thereby preventing carcinogenesis (98, 99).  Indeed, apoptosis is one of main 
mechanisms through which many chemopreventive agents, including curcumin, act.  
Apoptosis molecular pathways were described well in a recent review by 
Sprick and Walczak (100).  Mainly, two different pathways leading to apoptosis have 
been identified – intrinsic and extrinsic pathways.  In spite of their different modes 
of apoptosis induction, both pathways involve the activation of a cascade of 
proteolytic enzymes known as caspases.  In the extrinsic pathway, also called death 
receptor-mediated pathway, cell death is initiated by stimulation of members of the 
tumor necrosis factor (TNF) receptor superfamily, termed death receptors, in plasma 
membranes.  Binding of death receptors by their ligands triggers intracellular 
binding of the adaptor-protein Fas-associated death domain (FADD) to the receptor, 
forming the death inducing signaling complex (DISC).  FADD serves to recruit pro-
caspase-8 into the complex, resulting in activation of pro-caspase-8.  Caspase-8 
triggers the activation of caspase-3.  In contrast, the intrinsic pathway is mediated by 
the mitochondria that regulate the formation of the caspase-9-activating complex, the 
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apoptosome.  Chemical stress is one of stimulants to trigger the formation of 
apoptosome by causing a breach in mitochondrial integrity and therefore a release of 
cytochrome c and other pro-apoptotic molecules.  Released cytochrome c, together 
with Apaf-1, recruits pro-caspase-9 to activate it and later trigger the activation of 
caspase-3.   
Many proteins are involved in the regulation of the apoptosis pathway.  The 
integrity of the mitochondrial membrane is regulated by the Bcl-2 family, which can 
be divided into three groups, anti-apoptotic, pro-apoptotic, and BH-3-only proteins 
(100).  Anti-apoptotic Bcl-2 members, like Bcl-2 and Bcl-x, serve to maintain 
membrane integrity.  Under normal conditions, BH-3-only proteins are inactive.  
Upon activation, they activate pro-apoptotic proteins, Bax and Bak,that breach 
mitochondrial integrity.  Pro-apoptotic Bid that belongs to BH-3-only proteins is 
activated by caspase-8-mediated cleavage, providing a link between the receptor-
mediated pathway and mitochondria-mediated pathway (100).  Also, apoptosis can 
be negatively regulated by cellular caspase-inhibitors such as IAPs that inhibit 
activation of caspases (100).  Heat shock proteins induced by various stresses are 
known to play a negative regulatory role in apoptosis (101, 102).  In addition, 
apoptosis is mediated or suppressed by other cell signaling pathways including c-Jun 
N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK), and NF-κB 
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pathways (84, 92, 103).  Therefore, cumulatively cell destination, death or survival, 
is determined. 
Many studies with different types of cells have showed that curcumin induces 
apoptosis and inhibits cell growth.  Curcumin, at a concentration of 10 µM, 
enhanced apoptosis in the breast cancer cell line, MCF-7, by p53-dependent Bax 
induction (74).  In human melanoma cells, apoptosis was induced by 60 µM 
curcumin through Fas receptor pathway, p53-independent (104).  On the other hand, 
25 µM curcumin induced apoptosis through activation of BID cleavage and 
cytochrome c release in the myelogenous leukemia cell line HL-60 (96).  Treatment 
of renal carcinoma Kaki cells with curcumin downregulated Bcl-2, Bcl-xL, and IAP, 
activating the release of cytochrome c, resulting in induction of apoptosis (105).  In 
HCT116 colon cancer cells, curcumin-induced apoptosis was mediated through JNK, 
a member of MAPK.  Curcumin treatment induced sustained activation of JNK and 
phosphorylation of c-Jun and a JNK-specific inhibitor prevents curcumin-induced 
apoptosis (84).  Therefore, curcumin-induced apoptosis is mediated by many 
different signaling pathways and this is largely dependent on the types of cells and 
concentration of curcumin. 
19 
 
Chapter 2. Effect of age on inhibition of ACF development 
by curcumin  
 
2.1 Introduction 
Colorectal cancer, one of the leading causes of deaths in the United States, is 
strongly associated with dietary factors.  Many compounds in food, including some 
nutrients, have been reported to promote colon cancer whereas some nutrients and 
many phytochemicals have been shown to have colon cancer preventive properties 
(106, 107).  Curcumin, the yellow pigment of rhizomes of Curcuma longa Linn., has 
been commonly used for flavoring and coloring as a powder called turmeric in South 
East Asia.  Curcumin has been gaining popularity as a supplement due to reported 
various biological activities that include its anti-inflammatory, antioxidative, anti-
bacterial and chemopreventive activities (78).   
Curcumin inhibits colorectal cancer in several animal models.  Feeding of 
0.2 % curcumin to azoxymethane (AOM)-treated F344 rats inhibited both incidence 
of colon tumor and multiplicity of tumor (71, 72).  Curcumin also decreased 
intestinal tumors in a familial adenomatous polyposis animal model (27, 42).  The 
study by Sharma et al. (108) provided preliminary information on human 
pharmacodynamic and pharmacokinetic properties of curcumin extract in patients 
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with colorectal cancer.   
However, preclinical studies aimed at identifying potential chemopreventive 
dietary compounds have been conducted almost exclusively with young animals.  
Curcumin is no exception.  Modulation of gene expression and oxidative stress 
through which dietary compounds may show chemoprevention are highly associated 
with age (109, 110).  Moreover, metabolism of curcumin, which can be affected by 
the age, may alter efficiency of chemoprevention by curcumin (111).  For these 
reasons, the current animal study design using young animals may not properly reflect 
chemopreventive activity of dietary compounds in human colon cancer, a disease of 
the aged.  The hypothesis of this study was that maturation and aging may alter the 
response to a dietary intervention.  This hypothesis was tested using curcumin, a 
well-established colon chemopreventive agent, and the aberrant crypt foci (ACF) 
model.  ACF are preneoplastic lesions of colorectal cancer and ACF with large 
multiplicity are closely associated with tumor development (62).  This study was 
conducted to investigate the effect of age on inhibition of early stage of colon cancer 
by curcumin.   
Cyclooxygenase (COX) enzymes catalyze conversion from arachidonic acids 
to prostaglandins (86).  Curcumin reduced COX activity in colonic mucosa and 
tumors from AOM-treated F344 rats (71).  COX-2 is highly expressed in colon 
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cancer and prevention of COX-2 expression suppresses progression of colon tumor 
(91, 112).  Zhang et al. (113) reported that curcumin inhibited bile acid and phorbol 
ester-induced COX-2 expression in gastrointestinal cell line.  In addition, curcumin 
specifically inhibited COX-2 expression in HT-29 cells whereas COX-1, 
constitutively expressed in most tissues, was not affected by curcumin (91).  As a 
result, colonic COX-2 expression levels were measured using immunohistochemistry 
in this study.  
We also investigated whether the age-related difference in response to dietary 
curcumin was colon specific.  Curcumin affects arachidonic acid metabolism in the 
liver and inhibits formation of AOM-induced prostaglandins (114).  Ramirez-Tortosa 
et al. (69) reported that an ethanol-aqueous extract obtained from curcumin lowered 
total plasma cholesterol in male rabbits fed 1.3% cholesterol diet.  Administration of 
500 mg of curcumin per day for 7 days reduced total serum cholesterol in healthy 
humans (115).  Therefore, liver COX-2 mRNA expression and total serum 
cholesterol were measured to determine whether age affected other tissues in response 
to dietary curcumin.  This study reports significant effects of age on response to 





2.2. Materials and Methods 
 
2.2.1 Experimental animals and diets  
Experimental animals were young (6 weeks), middle-aged (12 months), and 
old (22 months) male F344 rats obtained from the colony at the National Institute of 
Aging (Bethesda, MD).  Six rats of each age group were randomly assigned to either 
AIN-93 containing 0.6% curcumin (Sigma, St. Louis, MO) or AIN-93 control diet.  
For the old group, 8 rats were allotted to each diet group because of their high risk of 
loss.  One week after starting on the experimental diet, all the rats were treated with 
azoxymethane (AOM, Sigma, St. Louis, MO) with 2 weekly s.c. injections (15 
mg/kg).  Rats were fed experimental diets for total 3 months, then were killed and 
colon, liver and serum were collected.  In the old group fed AIN-93 diet, two months 
after the first injection of AOM, one rat was found dead and another rat was killed 
because of significant weight loss.  Two of old rats fed curcumin showed lower food 
consumption and body weights through the whole experiment even though they 
recovered their body weight within 10 days after AOM injections.  Therefore, two 






2.2.2 Aberrant crypt foci evaluation 
Whole colons were flushed with 1 X phosphate buffer saline and opened.  
Colon pieces fixed in 4% paraformaldehyde were stained with 0.2% methylene blue 
as previously described (116).  Number, multiplicity (number of crypts per focus) 
and distribution of ACF were recorded.  ACF with 5 and 2 multiplicity in a colon 
stained with methylene blue are shown in Fig. 1.  ACF were evaluated from whole 
colon except for a short segment taken from the middle 2 cm toward the cecal end.  
This segment was used later for RNA isolation.  The RNA obtained from that tissue 
was of poor quality and could not be subsequently used to study changes in gene 




Figure 1. Aberrant crypt foci (arrows) in a rat colon stained with methylen blue. Focus 
with 5 multiplicity is on the left and 2 multiplicity on right.   
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2.2.3 Liver cyclooxygenase-2 mRNA expression 
Total cellular RNA from liver was extracted by the use of TRIzol Reagent 
(Invitrogen, Carlsbad, CA).  RNA samples were treated with DNAse-I enzyme using 
the DNA-free kit (Ambion Inc., Austin, TX).  First strand synthesis was performed 
using Retroscript kit (Ambion Inc.) and concentration of cDNA was measured 
spectrophotometrically. 
Cyclooxygenase-2 gene expression was studied using mouse COX-2 gene-
specific Relative RT-PCR Kit (Ambion Inc.).  Ribosomal gene 18S (498 bp) was 
used as an internal control.  The 18S primer:competimer ratio was optimized 
according to the manufacturer’s instructions before changes in expression of COX-2 
gene (297 bp) were analyzed.  After optimization of PCR assay conditions (DNA 
Engine, MJ Research, Waltham, MA), the multiplex reaction contained 1X complete 
reaction buffer; 200 µM dNTPs mixture; 0.4 µM 18S primers:competimers (1:9) 
mixture; 0.4 µM COX-2 primer and 0.5 U/25 µl Taq DNA polymerase.  The 
following thermocycling conditions were used for PCR assays: one 2-min cycle at 92 
oC followed by 27 cycles of denaturation for 30 s at 92 oC, annealing for 30 s at 59 oC , 
and extension for 1 min at 72 oC .  The final extension was given for 5 min at 72 oC 
before analysis of the PCR products.   
The PCR products from multiplex reactions were quantified using DNA 500 
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LabChip® and Agilent 2100 bioanalyzer according to the manufacturer’s protocol.  
Changes in the gene expression were determined by calculating the ratio of COX-2 
mRNA to 18S mRNA.  The ratios were calculated from the area under the curve 
values for each PCR product. 
 
2.2.4 Cyclooxygenase-2 immunohistochemisty  
To determine whether age or diet affects expression of COX-2 gene product 
in the colon, four pieces of tissues from different locations of the formalin-fixed 
colons were longitudinally embedded in paraffin, sectioned and immunostained for 
COX-2.  Deparaffinized tissue sections were incubated with 3% hydrogen peroxide 
and 2% normal goat serum to block endogenous peroxidase activity and non-specific 
binding sites, followed by incubation with rabbit polyclonal anti-murine COX-2 
antibody (Oxford BioMedical Research, Oxford, MI) diluted 1:1000.  Biotinylated 
anti-rabbit igG incubation was followed by amplification using the Vectastain ABC 
peroxidase kit (Vector Laboratories, Burlingame, CA).  Color was developed by 
treatment with diaminobenzidine tetrahydrochloride (DAB, Sigma).  Slides were 





2.2.5 Total serum cholesterol  
Blood was collected by cardiac puncture and centrifuged at 3000 rpm for 20 
minutes after clotting.  Collected serum was frozen at -80 oC until analysis.  Serum 
cholesterol was measured with the RefLab® cholesterol reagent (Fisher Scientific, 
Pittsburgh, PA) using a Beckman 640 spectrophotometer (Beckman Instruments, Inc., 
Fullerton, CA). 
 
2.2.6 Data analysis  
One-way analysis of variance (ANOVA) was conducted for the all data 
analyses using SAS software (8.1, SAS Institute Inc, Cary, NC) to determine if there 
were significant differences between rats fed curcumin and control diets.  Two-way 
ANOVA was performed to examine the effect of age and diet and their interaction on 
the number of ACF with 2 and over multiplicity.  Repeated measured analysis was 





2.3.1 General observations 
Average food consumption of each group of rat is shown in Table 1.  
Curcumin did not change food consumption in either middle-aged or old rats.  
However, food consumption was slightly higher in young rats fed curcumin (p < 0.05) 
compared to young rats fed the control diet.  When repeated measured analysis was 
performed for each time period, there was no difference (p > 0.05) in body weights of 
rats fed AIN-93 control diet (AIN) and AIN-93 containing 0.6% curcumin diet (CUR) 
in all age groups (Fig. 2).  Both middle-aged and old rats took longer than young rats 
to regain weight loss resulting from the AOM injections (Fig 2).  
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Table 1. Food consumption of different age groups of rats 
Age 
Dieta)
Young Middle-aged Old 
AIN 13.9 ± 0.3b) 14.9 ± 0.5 13.3 ± 0.5 
CUR 15.2 ± 0.5c) 14.8 ± 1.0 14.3 ± 0.5 
a) AIN represents the group fed the AIN-93 control diet and CUR represents the group 
fed the AIN-93 diet containing 0.6% curcumin 
b) g/day, mean ± SE, n=5-6 rats/group 





















Figure 2. Average body weight (mean ± SE, n=5-6 rats/group). YA: young rats fed 
AIN (AIN-93 control diet), YC: young rats fed CUR (AIN-93 diet containing 0.6% 
curcumin), MA: middle-aged rats fed AIN, MC: middle-aged rats fed CUR, OA: old 
rats fed AIN, OC: old rats fed CUR. Rats were given 2 weekly s.c. injections of AOM 
(arrow) one week after starting their experimental diets. 
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2.3.2 Aberrant crypt foci evaluation 
Two-way analysis of variance (diet × age) revealed a significant effect of diet 
(p < 0.01) on ACF number, and a significant interaction between diet and age (p < 
0.05).  As shown in Fig. 3, a significant inhibition of ACF by curcumin was 
observed only in young and old but not in middle-aged rats.  The number of ACF in 
young and old rats was lower in curcumin-fed rats by 49% and 55% respectively (p < 
0.05).  In contrast, there was no difference (p > 0.05) in the number of ACF between 
the two diet groups in middle-aged rats.  Age-related differences were also found in 
the inhibition of different size categories of ACF (Fig. 4).  In young rats, the 
reduction in ACF in curcumin-fed rats was observed mainly in small ACF (2 and 3 
multiplicity).  In contrast, the numbers of ACF in all size categories were not 
significantly different in the two diet groups in middle-aged rats.  In old rats, there 
were fewer ACF in all size categories in the curcumin-fed group.  The distribution of 
ACF throughout the whole colon is shown in Fig. 5.  The majority of the ACF in old 
rats were located in the distal to mid-colon in both groups of rats fed CUR and AIN.  
Distribution of ACF in young and middle-aged rats was similar to that of old rats and 






















Figure 3. Reduction in number of ACF with 2 and over multiplicity by curcumin in 
different ages of rats (mean ± SE, n=6 rats/group). AIN is the group fed the AIN-93 
control diet and CUR is the group fed the AIN-93 diet containing 0.6% curcumin. * 
represents significant differences (p < 0.05) between AIN and CUR groups in each 































Figure 4. Number of ACF in multiplicity categories of 2 and 3, 4 and 5, and 6 and 
over in rats fed either the AIN-93 diet (AIN) or the AIN-93 diet containing 0.6% 
curcumin (CUR) (mean ± SE, n=6 rats/group). A is multiplicity category of 2 and 3 
multiplicity, B is multiplicity category of 4 and 5 multiplicity and C is multiplicity 




Figure 5. Distribution of ACF in the colon of old rats (mean ± SE, n=6 rats/group) fed 
either the AIN-93 diet (AIN) or the AIN-93 diet containing 0.6 % curcumin (CUR). 
Data are depicted for every 2 cm of colon. A 2 cm segment from middle to cecal end 






















2.3.3 Colonic cyclooxygenase-2 immunohistochemistry 
The level of COX-2 protein expression in the normal-appearing colon tissue 
detected by immunostaining was very low in all animal groups (data not shown).  
Therefore, we were unable to determine conclusively whether COX-2 protein 
expression in early stage colon carcinogenesis was affected by age or dietary 
curcumin.  
 
2.3.4 Liver cyclooxygenase-2 mRNA expression   
Liver COX-2 mRNA expression levels increased as age increased, in both 
AIN and CUR groups (Fig. 6).  In all age groups, curcumin-fed rats had similarly 
lower (p < 0.05) COX-2 mRNA levels compared to AIN-fed rats: 35% lower in young, 

























Figure 6. Effect of curcumin on liver cyclooxygenase-2 mRNA expression in relation 
to 18S mRNA in different aged rats (mean ± SE, n=5-6 rats/group). AIN is the group 
fed the AIN-93 control diet and CUR is the group fed the AIN-93 diet containing 
0.6% curcumin. Cyclooxygenase-2 mRNA expression levels were normalized to 
expression levels of an internal control, 18S gene. * represents significant differences 
(p < 0.05) between AIN and CUR groups in each age group by ANOVA.  
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2.3.5 Total serum cholesterol level 
Total serum cholesterol levels increased as age increased (Fig. 7).  Middle-
aged and old rats had higher (p < 0.05) total serum cholesterol levels compared to 
young rats in the control diet group.  Cholesterol levels were higher (p < 0.05) in 
young rats fed curcumin than in young rats fed the control diet.  In middle-aged and 
old rats, serum cholesterol levels were not significantly affected by curcumin feeding.   
 
2.3.6 Macroscopic and histopathological observations  
Tissues obtained from the study were observed and evaluated by a pathologist.  
Macroscopic and histopathological changes in different tissues by age or diet are 



























Figure 7. Effect of curcumin on serum total cholesterol levels in different ages of rats 
(mean ± SE, n=5-6 rats/group). AIN is the group fed the AIN-93 control diet and CUR 
is the group fed the AIN-93 diet containing 0.6% curcumin. * represents significant 
differences (p < 0.05) between AIN and CUR groups in each age group by ANOVA. # 





The most important finding of this study is the significant effect of age on 
inhibition of the development of early stages of colon cancer by dietary curcumin.  A 
significant age-related difference was found in inhibition of colonic ACF development 
by 0.6 % dietary curcumin.  Rao et al. (71) and Kawamori et al. (72) showed that 
curcumin effectively inhibits colon tumor in young F344 rats.  Interestingly, in this 
study, curcumin effectively inhibited the number of ACF in young and old rats 
whereas ACF growth and development in middle-aged rats was not affected by 
curcumin (Fig. 3).  The number of large ACF is more predictive of tumor 
development than total number of ACF (62).  In young rats, feeding curcumin more 
effectively inhibited smaller ACF than larger ACF.  On the other hand, old rats fed 
curcumin had a much lower number of ACF in all categories.  In middle-aged rats, 
curcumin did not inhibit the number of ACF in any size of category.   
It is unclear how curcumin affects progression of small ACF to large ACF.  
Small ACF (2 and 3 multiplicity) may be more susceptible to curcumin and selected 
small ACF resistant to dietary curcumin may progress into more advanced stages.  
Another possible explanation would be that large, advanced ACF might be more 
resistant to curcumin.  The study of Magnuson et al. (62) showed that feeding of 
cholic acid to AOM-treated rats reduced the number of small ACF, but increased the 
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growth of large, resistant ACF and the tumor incidence.  ACF in rats fed the AIN-76 
diet containing 0.2% cholic acid had lower number of apoptotic bodies per 100 cells 
than ACF in rats fed AIN-76 control diet (62), demonstrating resistance to the 
cytotoxic effect of cholic acid. 
Age also affected ACF development.  There was a trend for reduced number 
of ACF in middle-aged and old rats as compared to young rats fed the control AIN-93 
diet in response to the same dose per body weight of AOM.  This is in contrast to a 
previous report (58) in which middle-aged female Sprague-Dawley rats developed a 
higher number of ACF than did young rats.  There are several differences between 
this study and the previous study including sex, strain and supplier of the rats, as well 
as diet.  In this study, F344 rats were obtained from the NIA aged animal colony at 
the aged 6 weeks, 12 months and 22 months, and the AIN-93 diet was used as the 
base diet.  The previous study (58) was conducted using female Sprague-Dawley rats 
from Simonsen Laboratories Inc, aged 4 and 50 weeks and fed standard rat chow.  
However, the study of Verghese et al. (117), which also used male F344 rats from the 
NIA colony and the AIN-93 diet, suggested that middle-aged rats were more sensitive 
to AOM.  Variations in development of colonic tumors and ACF due to strain, sex, 
animal supplier and diet have been reported previously (118).  Chung and colleagues 
(119) recently reported that when C57BL/6JNIA mice were given the same per body 
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weight dose of AOM, old male mice (21-22 mo) developed significantly more ACF 
than did young mice (4-5 mo).  However, when the same total dose was delivered, 
young mice developed more ACF, presumably due to the higher dose per body weight.  
Dix (5) suggested that increase of cancer incidence with age might be caused by 
change of cell proliferation rate with age.  However, Magnuson et al. (58) reported 
that cell proliferation rate determined by bromodeoxyuridine labeling index was 
similar between 4 and 50 weeks of age although there was age-related difference in 
ACF development.  Also, Chung et al. (119) showed that age-related susceptibility to 
AOM is not due to differences of COX-2 expression, cell proliferation, or AOM 
hydroxylase activity in C57BL/6JNIA mice.  At this time, it is not clear whether 
young animals are more susceptible to AOM-induced colon carcinogenesis than are 
old animals, or what factors may influence the effect of age.  
The precise mechanisms by which age affects response to dietary curcumin 
are not known.  A possible explanation may be differences in the absorption, 
metabolism, and/or excretion rate of curcumin due to age.  Dybing and Soderlund 
(120) reported decreased metabolism in the very young and old, and proposed that 
newborns and elderly may be more sensitive to xenobiotics whose toxicity is due to 
the parent compound.  Ireson et al. (111) showed that curcumin metabolites 
differently inhibited phorbol ester-induced prostaglandin E2 (PGE2) production – 
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curcumin reduced PGE2 levels to control levels whereas tetrahydrocurcumin, 
hexahydrocurcumin, and curcumin sulfate had much less inhibitory activity, and 
hexahydrocurcuminol was inactive.  Therefore, the relative amount of curcumin and 
each curcumin metabolite may affect biological activity of curcumin in vivo.  
However, several studies on the pharmacokinetics of curcumin (121-124) have 
illustrated that metabolites of curcumin are only detectable in plasma when high dose 
of curcumin, followed by rapid sampling.  Pan et al. (123) reported that when 
curcumin was administered orally in a bolus dose (1.0 g/kg), curcumin was below 
detection level within 6 hours and existed as conjugate or reduced form in plasma.  
Sharma et al. (125) reported curcumin levels in the liver and colon mucosa from 
female F344 rats fed 2 % curcumin for 14 days.  They were able to measure 
curcumin from liver and colon mucosa but curcumin glucuronide and curcumin 
sulfate were below detection limit.  Therefore, it was unlikely to be able to measure 
curcumin and all metabolites from tissues of rats fed 0.6% curcumin.   
We attempted to estimate the biological activity of curcumin in the three ages 
of rats using changes in serum cholesterol, COX-2 mRNA in the liver and COX-2 
protein expression in the colon.  Several studies have demonstrated that curcumin is 
involved in cholesterol metabolism.  Hypocholesterolemic properties of curcumin in 
male rabbits (69) and in healthy humans who did not have a high fat or high 
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cholesterol diet (115) have been reported.  In this study, curcumin did not reduce 
total serum cholesterol levels in either middle-aged or old rats.  On the contrary, 
curcumin increased serum total cholesterol in young rats, which had initial lower total 
serum cholesterol levels than middle-aged and old rats.  Most previous animal 
studies used high fat and high cholesterol diets to investigate the hypocholesterolemic 
effect of curcumin (69, 126), although a high fat or high cholesterol diet was not 
applied in the human study where 500 mg of curcumin per day for 7 days reduced 
total serum cholesterol (115).  Therefore, total serum cholesterol levels in the rats in 
this study may not have been high enough to see hypocholesterolemic effect of 
curcumin.  Harris (127) reviewed the effects of n-3 fatty acids on serum lipid and 
lipoprotein concentrations in seven species of experimental animals.  In all 
experimental animals, n-3 fatty acids apparently reduced high-density-lipoprotein-
cholesterol (HDL) concentrations, which is never observed in humans with fish-oil 
supplementation.  It was suggested that these differences between animals and 
humans were caused by species differences in lipoprotein metabolism and differences 
in experimental design (127).  Mela et al. (128) also postulated that differences in 
plasma HDL responses to adiposity in humans and experimental animals would arise 
by species differences in lipoprotein metabolism.  Therefore, changes in total serum 
cholesterol may not be a good measure of curcumin activity in rats.  
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Sharma et al. (125) suggested that both colon mucosa and liver are target 
organs of curcumin as feeding 2 % dietary curcumin for 14 days elevated glutathione-
S-transferase levels in the liver and reduced levels of malondialdehyde-
deoxyguanosine adduct in colon mucosa.  AOM is generally used to induce colon 
cancer and causes formation of prostaglandins from arachidonic acid as a result of 
inducing COX-2 expression in the colon (71).  Liver is a major organ where not only 
curcumin but also AOM are metabolized and where prostaglandin formation is 
induced by AOM (114).  Rao et al. (114) reported that curcumin suppressed AOM-
induced prostaglandin and thromboxane in the liver and colonic mucosa of young 
male F344 rats.  Therefore, liver COX-2 mRNA and colonic COX-2 protein levels 
were measured to compare the biological activity of curcumin in the three ages of rats.  
Liver COX-2 mRNA expression increased as age increased, but curcumin reduced 
COX-2 mRNA expression to similar extent in three ages of rats, suggesting similar 
levels of biologically active curcumin in the liver (Fig. 6).  This result indicates that 
age-related differences in the absorption or metabolism of curcumin were not 
occurred.  
As has been reported previously for normal and preneoplastic colonic tissues 
(46), the levels of COX-2 were not high enough to detect using 
immunohistochemistry, preventing the determination of whether age or curcumin 
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reduced colonic COX-2 expression.  Therefore, in contrast to the age-related 
difference in inhibition of colonic ACF by curcumin, any other age-related difference 
in response to curcumin was not detected.  This age-related difference is more likely 
due to age-related differences in cellular events relevant to colon carcinogenesis rather 
than in curcumin absorption or metabolism.   
In conclusion, these results demonstrate that age affects inhibition of early 
stage of colon carcinogenesis by curcumin.  Further investigations are needed to 
determine whether aging affects responses to other dietary interventions in colon 
carcinogenesis or whether this effect is limited to curcumin, and whether age also 
affects inhibition of advanced tumor development by curcumin.  These results 
suggest that the effect of age should be considered in preclinical study designs of 
dietary interventions to determine whether age-related differences may be at least 
partially responsible for lack of correlation of efficacy of dietary interventions in 
animal and human colon cancer intervention trials.   
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Chapter 3. Confirmation of lack of preventive effect of 
curcumin on ACF development in middle-aged rats 
 
3.1 Introduction 
Age is a single potent factor contributing to the incidence of cancer, including 
colorectal cancer.  Most of cancers derived from epithelial cells onset at the age of 
about 40 and after that exponentially increase with age both in men and women (3).  
Although it is unclear how the aging process is involved in carcinogenesis, the 
microenvironment of the organism seems to have a significant effect on determining 
the progression of the malignant phenotype.  Successive studies of McCullough et al. 
(8-10) showed that the development of tumors from liver epithelial cancer cells was 
affected by changes in tissue microenvironment and that the aging process causes 
such alterations in the tissue environment.  Krtolica et al. (11) also reported that 
senescent fibroblasts stimulate growth of premalignant cells both in vitro and in vivo.  
These findings suggest that the microenvironment can modulate tumor development 
from initiated cancer cells and aging process may contribute alteration of tissue 
environment, promoting initiated cancer cells to grow malignant tumors.   
The significance of the microenvironment in carcinogenesis led us to 
hypothesize that the aging process may also affect chemoprevention by dietary 
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compounds.  Interestingly, the previous study showed no inhibition of formation of 
aberrant crypt foci (ACF), putative lesions of early colon cancer, by dietary curcumin 
only in middle-aged rats compared to effective reduction in young and old rats 
(Chapter 2).  This loss of preventive activity of curcumin in middle-aged rats was a 
novel finding, with important implications for human intervention trials.  Therefore, 
it was important to confirm this observation and to further investigate potential 
mechanisms responsible.  Age-related differences in the response in the colon rather 
than in curcumin metabolism seemed to be responsible for our finding as liver COX-2 
mRNA expression, an indicator of biological activity of curcumin, was similarly 
affected by curcumin in all ages (129).   
Curcumin is a polyphenolic compound imparting the yellow color in the spice 
turmeric, powdered rhizome of Curcuma logna Linn.  The chemopreventive activity 
of curcumin in young animal models and in colon cancer cell lines is well established 
(27, 42, 71, 72, 82-84).  However, the chemopreventive activity of curcumin in 
middle-aged or old animals had not been previously reported.   
The anti-inflammatory activity of curcumin has been postulated as a mechanism of 
colon cancer prevention.  In general, COX is a rate-limiting enzyme catalyzing 
conversion of arachidonic acid into prostaglandins.  Two forms, COX-1 and COX-2, 
are known.  COX-1 is constitutively present whereas COX-2 is induced by cytokines, 
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mitogens, and tumor promoters, and mediates the inflammatory process (86).  Many 
studies have reported that COX-2 is highly expressed in colon tumors (87-89) and 
inhibition of COX-2 as a mean of colon cancer prevention has been reviewed by 
Gupta and DuBois (90).  Curcumin inhibited phospholipases, responsible for 
generation of arachidonic acid from membrane phospholipids and formation of 
prostaglandin E2 (PGE2), both in colon tumors and colon mucosa (71).  Curcumin 
treatment also inhibited COX-2 expression at both mRNA and protein levels in HT-29 
colon cancer cells (91).  The effect of dietary curcumin on arachidonic acid 
metabolism has not been investigated in the colon at the stage of ACF formation in 
either young or older animals.  In the previous study (Chapter 2), curcumin inhibited 
COX-2 mRNA expression in all ages in the liver but the effect of curcumin on colonic 
COX-2 protein expression estimated by immunohistochemisty was not determined 
due to very low expression in all groups.  Therefore, this study duplicated the ACF 
study with only middle-aged rats to confirm previous findings of resistance of middle-
aged rats to curcumin chemoprevention and investigated if the lack of 
chemoprevention by curcumin in middle-aged rats is due to a failure of inhibition of 
COX-2.  
This study reports confirmation of the previous findings – middle-aged male 
F44 rats are resistant to the chemopreventive activity of curcumin against AOM-
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induced colon carcinogenesis.  Transcriptional levels of COX were lower in the liver 
but higher in the colon of middle-aged rats fed the curcumin diet.  There were no 
age-related differences in colon COX expression in rats either untreated or treated 
with AOM.  Shortly after AOM treatment, colonic COX-1 mRNA levels were 
reduced in all ages of rats whereas COX-2 mRNA levels were not affected by AOM 
in any age group.  It should be further studied whether curcumin similarly increases 
COX expression in the colon of young rats.   
 
3.2 Materials and Methods 
 
3.2.1 Experimental animals and diets  
In all the studies, experimental animals were male F344 rats obtained from 
the colony at the National Institute of Aging (NIA, Bethesda, MD).  Young, middle-
aged, and old rats were treated at the age of 6 weeks, 12 months, and 22 months, 
respectively.  Control diet was AIN-93 diet (AIN) and experimental diet was AIN-93 
diet containing 0.6% curcumin (CUR) prepared by Dyets (Dyets, Inc., Bethlehem, 





Experiment 1. Effect of curcumin on colonic ACF formation and 
arachidonic acid metabolism in the colon and the liver of middle-aged rats: To 
confirm the previous observation (Chapter 2) of resistance of chemoprevention in 
middle-aged rats, and to investigate the effect of curcumin on colonic arachidonic acid 
metabolism, we followed our previous experimental protocol (Section 2.2.1) using 
only middle-aged rats, and increased the number of animals per group.  Twenty 
middle-aged rats were randomly assigned to either CUR or AIN diets.  One week 
after starting their experimental diets, all the rats were given 2 weekly s.c. injections 
(15 mg/kg body weight) of azoxymethane (AOM, Sigma) and were maintained on 
their experimental diets.  Three months after the first AOM injection, the rats were 
killed.  Tissue collection and assays are described below.  Transcriptional levels of 
COX-1 and COX-2 were measured in collected colon mucosa and livers.  Also, 
colonic PGE2 levels were evaluated.  Two rats fed the AIN-93 diet were found dead 
3 days after the second injection of AOM and one rat fed curcumin diet was 
incorrectly injected with lower dose of AOM.  Data from those 3 rats were removed 
from all analyses.  
 
Experiment 2. Effect of AOM on colonic cyclooxygenase in three 
different ages of rats: The effect of AOM treatment on the colonic COX-1 and COX-
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2 mRNA expression was tested in three different ages of animals.  Groups of 12 
young, middle-aged, and old male F344 rats were obtained.  Six rats in each age 
group were randomly given a single injection of either AOM (15 mg/kg body weight) 
or saline after being fed AIN-93 diet for one week.  Rats were killed 0 (saline 
control) or 24 hours after the AOM injection and colons were collected for 
measurement of COX-1 and COX-2 mRNA levels. 
 
3.2.2 Tissue collections 
Colons were immediately placed on a cold surface and scraped to collect 
mucosa.  Half of the mucosa from each rat was fixed in RNAlater (Ambion Inc, 
Austin, TX) for RNA isolation and the rest was frozen at –80 oC for the PGE2 
immunoassay.  Collected livers were stored at –80 oC until analyzed.  
 
3.2.3 Aberrant crypt foci evaluation 
Whole colons were flushed with cold 1 X phosphate buffer saline and opened 
longitudinally.  ACF were evaluated as described in previous studies (Section 2.2.2), 
(116) from whole colon except for 2 cm of distal colon which was scraped and treated 




3.2.4 Cyclooxygenase-1 and 2 mRNA expression using RT-PCR 
Total RNA was isolated from the liver and the colon mucosa using TRIzol 
Reagent (Invitrogen, Carlsbad, CA).  cDNA was generated using Retroscript kit 
(Ambion Inc., Austin, TX).  An aliquot of cDNA was subjected to RT-PCR for COX-
1 or COX-2 genes as described previously (Section 2.2.3).  Briefly, gene expression 
levels of COX-1 and COX-2 were measured using the mouse COX-1 (401 bp) and 
COX-2 (297 bp) gene-specific Relative RT-PCR Kit (Ambion Inc.), respectively, 
relative to 18S (498 bp), primer:competimer (1:9).  18S mRNA was used to 
normalize COX gene expression to control for possible differences in loading.  The 
PCR conditions for COX-1 and COX-2 genes were the same as described in the 
previous study (Section 2.2.3) with exceptions that an annealing temperature for 
COX-1 was 61 oC and the number of thermocycles was 27 and 29 for the colon and 
the liver cDNAs, respectively.  The levels of PCR products of COX-1, COX-2 and 
18S were determined using DNA 500 LabChip® and Agilent 2100 bioanalyzer 
(Agilent Technologies Inc., Palo Alto, CA) and the ratio of PCR products of COX-1 
or COX-2 to 18S were generated.   
 
3.2.5 Prostaglandin E2 using enzyme immunoassay  
Frozen colon tissues were homogenized with 50 mM TRIS buffer (pH 7.5) 
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containing 10 µM indomethacin (MP Biomedicals, Aurora, OH).  Colon 
homogenates were acidified with 2M HCl to pH 3.5 and extracted 3 times with ethyl 
acetate (10 times of homogenates in volume).  Collected ethyl acetate layers 
following centrifugation at 5,000 g for 5 min were evaporated to dryness under N2 
and reconstituted with the assay buffer for measurement of PGE2 using the 
prostaglandin E2 enzyme immunoassay kit (Assay Designs Inc., Ann Arbor, MI).  
Results were expressed as pg PGE2/mg wet tissue.  
 
3.2.6 Data analysis  
One-way analysis of variance (ANOVA) was conducted for the all data 
analyses using SAS software (8.1, SAS Institute Inc, Cary, NC) to determine if there 
were significant differences between any two groups.  Two-way ANOVA was 
performed to examine the effect of age and azoxymethane treatment and their 










3.3.1 Experiment 1. Effect of curcumin on colonic ACF formation and 
arachidonic acid metabolism in middle-aged rats 
Aberrant crypt foci evaluation: As shown in Table 2, there was no 
significant difference between rats fed curcumin (CUR) and control (AIN) diet in 
either the total number of ACF or any category of ACF multiplicity.  ACF 
multiplicity is a measure of progression of ACF and is equal to the number of aberrant 
crypts per focus (62).  P-values tended to become close to 1 as multiplicity increased.  
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Table 2. Number of ACF in different categories of multiplicity in middle-aged rats 
 Categorya)
Dietb)  
Total 2-3 4-5 6-9 >10 
AIN 244.3 ± 18.2 113.4 ± 8.5 34.6 ± 5.6 21.8 ± 6.4 5.3 ± 2.0 
CUR 204.1 ± 12.6 95.4 ± 7.7 28.3 ± 2.4 22.9 ± 3.6 5.8 ± 1.2 
p – valuec) 0.0937 0.1375 0.3270 0.8799 0.8258 
a) ACF were categorized by their multiplicity  
b) AIN is AIN-93 control diet and CUR is AIN-93 diet containing 0.6% curcumin  
c) There were no significant differences (p > 0.05) between diet groups in any 
category of ACF multiplicity by ANOVA.   
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Cyclooxygenase mRNA expression and colonic prostaglandin E2 levels:  
In the liver, rats fed the curcumin diet had significantly lower (p < 0.05) levels of both 
COX-1 and COX-2 mRNA compared to rats fed the control diet (Fig. 8).  On the 
contrary, colonic COX-2 mRNA levels were significantly higher (p < 0.05) in the 
curcumin diet group compared to the control diet group.  Feeding 0.6% curcumin did 
not significantly affect (p > 0.05) either colonic COX-1 mRNA expression (Fig. 8, A) 
or PGE2 levels (Fig. 8, B).  In the liver, transcriptional levels of COX-2 were much 
lower than COX-1 whereas in the colon, the relative levels of COX-2 to COX-1 



































































Figure 8. Effect of curcumin on arachidonic acid metabolism in middle-aged rats 3 
months after the AOM injection (mean ± SE, n=8-9 rats/group). AIN is the group fed 
the AIN-93 control diet and CUR is the group fed the AIN-93 diet containing 0.6% 
curcumin. Transcriptional levels of COX-2 and COX-1 in relation to 18S in the liver 
(upper) and the colon (lower, A). PGE2 levels in the colon (lower, B). Data values of 
COX-2 mRNA were log transformed due to large difference in variance between two 
diet groups. * represents significant differences (p < 0.05) between AIN and CUR by 
ANOVA.   
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3.3.2 Experiment 2. Effect of AOM on colonic cyclooxygenase mRNA levels in 
three different ages of rats  
Dietary curcumin differentially affected the levels of COX expression in the 
liver and the colon mucosa of middle-aged rats.  The increased colonic COX 
expression in curcumin-fed rats was unexpected.  Therefore, it was investigated 
whether colonic COX mRNA expression is differently affected by AOM treatment in 
different aged rats.  The levels of colonic COX-1 and COX-2 mRNA were examined 
in three different ages of rats treated with either AOM or saline.  
As shown in Fig. 9, COX-2 mRNA levels were not significantly affected (p > 
0.05) by AOM treatment in any age group.  Two-way analysis of variance (age × 
AOM treatment) also showed no significant age, treatment, or interaction effects for 
COX-2.  In contrast, in every age group, rats treated with AOM had lower levels of 
colonic COX-1 mRNA levels 24 hours following injection.  When two-way ANOVA 
was performed, there was a significant AOM effect (p < 0.05) whereas neither the 
effect of age or interaction of age and treatment were significant.  The levels of 
colonic COX-1 and COX-2 were similar among all ages of animals within the same 
treatment group (Fig. 9).  Therefore, transcriptional levels of COX-1, but not COX-2, 










































Figure 9. Effect of AOM on colonic mRNA expression of COX-2 (upper) and COX-1 
(lower) in relation to 18S expression in three different ages of rats at 0 (saline 
treatment) or 24 hours after AOM injection (mean ± SE, n=6 rats/group). Two-way 
ANOVA showed a significant effect (p < 0.05) of AOM treatment on colonic COX-1 




This study sought to confirm previous findings of age-related differences in 
chemoprevention by curcumin and explore possible mechanisms.  As described in 
Chapter 2, the chemopreventive activity of curcumin determined by inhibition of 
AOM-induced ACF was not observed in middle-aged rats, while significant 
chemoprevention was observed in young and old rats.  Resistance of middle-aged 
rats to colonic chemoprevention by dietary curcumin is a significant observation.  It 
is middle-aged to older individuals who are targeted for prevention of cancer.  
However, young animals have been exclusively used in preclinical studies.  As 
shown in Table 2, the number of ACF did not significantly differ by diet group in any 
multiplicity category of ACF and this was even more apparent in larger ACF 
(multiplicities of 6-9 and >10), indicating no chemopreventive effect of curcumin.  
Rats fed curcumin did have significantly lower levels of both COX-1 and COX-2 
mRNA in the liver (Fig. 8) as observed previously (Section 2.3.4).  Therefore, this 
study reproduced and confirmed previous findings – middle-aged animals are resistant 
to the chemopreventive activity of curcumin against AOM-induced colon 
carcinogenesis.  
This study also investigated if arachidonic acid metabolism is potentially 
involved in the lack of curcumin chemoprevention in middle-aged rats.  Previous 
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studies have suggested that high expression of COX-2 and COX-2-metabolites such 
as PGE2 are involved in colon carcinogenesis (48, 71, 130, 131).  Modulation of 
arachidonic acid metabolism by inhibiting the COX-2 enzyme is considered an 
effective mechanism for anticarcinogenic action of chemopreventive agents including 
curcumin (90).  Earlier studies reported that curcumin inhibited the enzyme activity 
of total COX in the colon mucosa of rats treated with AOM (114) and reduced ex-vivo 
production of PGE2 in AOM-induced colon tumors (71).  A more recent study 
showed that curcumin treatment inhibited COX-2 expression at both mRNA and 
protein levels in HT29 colon cancer cells which highly express COX-2 (91).  
However, the effect of dietary curcumin on arachidonic acid metabolism was not 
investigated in ACF stage of AOM-induced colon carcinogenesis in either middle-
aged or young animals.  In previous our ACF study (Chapter 2), the poor quality of 
RNA in formalin-fixed colon tissues made difficult to evaluate COX-2 mRNA 
expression.  Colonic COX-2 protein levels were very low in all age and diet groups 
as determined by the immunohistochemical staining method.  Therefore, in this 
study, we investigated the effect of curcumin on arachidonic acid metabolism in the 
colonic mucosa by measuring COX-2 mRNA and PGE2 levels in middle-aged rats.  
Surprisingly, in contrast in the liver, COX-2 was not inhibited in the colon of middle-
aged rats fed curcumin, but significantly higher COX-2 mRNA levels were observed 
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(Fig. 8A).  Inhibition of colonic PGE2 production through inhibiting COX-2 enzyme 
activity has been targeted for colonic chemoprevention (90) and considered one of the 
anticarcinogenic mechanisms of curcumin as reviewed above.  Thus, the results in 
the colon gave a rise to the speculation that the lack of inhibitory effect of dietary 
curcumin on arachidonic acid metabolism might be the cause of failure of colonic 
chemoprevention by curcumin in middle-aged rats.  
However, four lines of evidence indicate the inhibition of ACF formation 
during initiation and early promotion stage of carcinogenesis by curcumin, a known 
COX inhibitor and colonic chemopreventive agent, may not be due to inhibition of 
COX-2 activity and PGE2 production in the colon.  First, the enhancing effect of 
AOM on colonic COX-2 expression or PGE2 production has not been demonstrated 
during initiation of AOM-induced colon carcinogenesis in spite of general agreement 
in over-expression of COX-2 and PGE2 in advanced tumors.  Colonic PGE2 levels 
were not significantly affected by two weekly injections of AOM at the stage of ACF 
formation in mice (132).  Takahashi et al. (46) reported that epithelial COX-2 
expression was only positive in large adenocarcinoma but not in either dysplastic or 
hyperplastic ACF, suggesting that the COX-2 expression levels in colonic ACF may 
be as low as in normal-appearing colon crypts.  COX-2 expression increased with 
advancement of colon cancer in AOM-treated rats (46) and sporadic human cancer 
63 
 
(133).  Secondly, it is not evident that inhibition of COX-2 activity and PGE2 
production is an effective mechanism to inhibit the initiation of colon carcinogenesis.  
Administration of rofecoxib, a selective COX-2 inhibitor, for six months to 1,2-
dimethylhydrazine-treated rats failed to inhibit ACF formation, but reduced later stage 
tumor progression (134).  Moreover, recent data suggest that many selective COX-2 
inhibitors have multiple chemopreventive mechanisms including induction of 
apoptosis, which might be important in inhibiting the initiation of cancer, in a COX-2 
independent pathway (135, 136).  Eklou-Kalonji et al. (137) also reported 
prostaglandin-independent effects of aspirin on cell growth and cell cycle in colon 
cancer cells.  Thirdly, there are no available data demonstrating that curcumin 
inhibits COX-2 or PGE2 under normal conditions in contrast to an apparent inhibitory 
effect on highly enhanced COX-2 expression and PGE2 production observed in colon 
tumors or induced inflammation (70, 111, 113).  Lastly, but not least, recent studies 
described below indicate the importance of COX-2 in maintaining gastrointestinal 
(GI) homeostasis (138-140).  Therefore, COX-2 inhibition may not be an 
anticarcinogenic mechanism during initiation of colon carcinogenesis and thus may 
not be responsible for the resistance to curcumin chemoprevention in middle-aged rats. 
In general, COX-2 expression is low under normal conditions and rapidly 
induced in response to inflammatory signals whereas COX-1 is constitutively 
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expressed in various normal tissues including the GI mucosa.  These differences in 
the COX isoforms lead to the idea that COX-1 has a housekeeping role in GI mucosa.  
As a result, inhibition of COX-1 but not COX-2 was considered to be responsible for 
the GI damage mainly due to deficiency of prostaglandins as seen in the use of non-
steroidal anti-inflammatory drugs (NSAID).  However, recent studies using different 
types of COX inhibitors have shown that inhibition of not only COX-1 but also COX-
2 is required for NSAID-induced GI injury (139, 140).  The administration of a 
conventional NSAID such as indomethacin causes hemorrhagic damage in the small 
intestine of rats (139) and small bowel ulcer in mice (140).  The combined 
administration of the COX-1 selective inhibitor and the selective COX-2 inhibitor 
induces such damage in the small intestine of rats (139) and mice (140).  However, 
the administration of either the selective COX-1 inhibitor alone or the selective COX-
2 inhibitor alone does not produce such damages (139, 140).  The study of 
Sigthorsson et al. (140) further supports the importance of COX-2 in maintaining 
integrity of GI mucosa, showing occurrence of an ileal ulcer that is distinguished from 
the ulcer caused by indomethacin in long-term COX-2 deficiency.  MacNaughton 
and Cushing (141) also reported constitutive expression of COX-2 mRNA and protein 
in mouse colon.  Therefore, these studies suggest that both COX-1 and COX-2 play 




In spite of recent researches emphasis on modulation of arachidonic acid 
metabolism in colonic chemoprevention, there were no reports on the effect of AOM 
on COX-2 expression in the colon.  Experiment 2 was conducted to determine 
whether colonic COX-1 and COX-2 mRNA expression is affected by the initiation of 
AOM-induced carcinogenesis in three different aged rats.  Basal COX-1 mRNA 
levels were similar among different ages of rats, and COX-1 mRNA expression was 
similarly inhibited shortly after AOM injection in all age groups (Fig. 9).  Also, 
curcumin alone does not seem to affect colonic COX-2 mRNA levels.  Feeding 0.6% 
curcumin for 10 days did not increase COX-2 mRNA expression in any age of rats not 
treated with AOM (unpublished observations).  This fact excludes the possibility that 
feeding curcumin increases basal levels of COX-2 mRNA expression only in the 
colon of middle-aged rats.  Therefore, effect of curcumin on arachidonic acid 
metabolism after AOM treatment should be examined in young rats in order to 
determine if failure of inhibition of COX-2 mRNA expression and PGE2 production 
in the colon contributes to the lack of chemoprevention by curcumin in middle-aged 
rat.  
In summary, in the middle-aged group, rats fed curcumin had higher COX-2 
mRNA levels in the colon in contrast to reduced COX mRNA levels in the liver.  
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AOM decreases COX-1 mRNA expression, and does not enhance COX-2 mRNA 
expression immediately following injection regardless of the ages of animals.  
Moreover, recent data do not support the contention that modulation of arachidonic 
acid metabolism plays an important role in preventing initiation of colon 
carcinogenesis.  Whether curcumin increases COX-2 mRNA expression in young 
rats as in middle-aged rats should be investigated during early stage of AOM-induced 
carcinogenesis to determine if arachidonic acid metabolism is involved in the 
resistance of middle-aged rats to curcumin chemoprevention.   
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Chapter 4. Effect of AOM and curcumin on transcriptional 
induction of Hsp70  
 
4.1 Introduction  
Curcumin did not inhibit the formation of colonic ACF in middle-aged rats, 
despite effective reduction of ACF in young and old (Chapter 2).  It is important to 
understand the underlying mechanism(s) responsible for resistance to curcumin 
chemoprevention in middle-aged animals as it is middle-age to older human 
population who are not only likely suffering from colorectal cancer but also targeted 
for dietary chemoprevention.  
Cyclooxygenase (COX) enzymes are known to be rate-limiting enzymes in 
production of prostaglandins from arachidonic acids.  Many epidemiological, 
clinical, and experimental studies (142-146) have reported a colonic chemopreventive 
effect of nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit COX activity 
(147).  In support of this implication of preventive effect of NSAIDs in colon cancer, 
high levels of COX-2 expression and PGE2 were reported in AOM-induced colon 
tumors as well as in familial adenomatous polyposis (FAP) and sporadic colon tumors 
(88, 148).  However, long-term use of traditional NSAIDs induces deleterious 
damage in the gastrointestinal mucosa probably due to reduced levels of 
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prostaglandins by inhibition of both COX-1 and COX-2 (139, 149).  Therefore, 
COX-2 specific inhibitors are attractive in chemoprevention of colon cancer.  
Curcumin is also known to be a COX inhibitor, although it is unclear whether 
curcumin is COX-2 specific or an inhibitor of both COX-1 and COX-2.  Zhang et al. 
(113) reported that curcumin specifically inhibited the expression of COX-2 without 
affecting the level of COX-1 in HT-29 colon cancer cells.  On the contrary, curcumin 
more effectively inhibited peroxidase activity of COX-1 compared to COX-2 in vitro 
(68).  A previous study (71) reported involvement of arachidonic acid metabolism in 
colonic chemoprevention by curcumin.  However, there is little evidence to suggest 
that modulation of arachidonic acid metabolism by curcumin is responsible for the 
age-related difference in inhibition of colonic ACF formation.  Available data do not 
support that COX-2 or PGE2 levels are elevated in initiation of colon carcinogenesis, 
the stage of ACF formation or earlier.  AOM treatment did not significantly affect 
the PGE2 levels in the colon of mice at the stage ACF form in either high-fat or low-
fat diet group (132).  In the previous study (Section 3.3.2), colonic COX-2 mRNA 
expression was not affected by AOM shortly after the treatment.  On the contrary, 
COX-1 mRNA levels were reduced in the colons of AOM-treated rats.  
The elevation of colonic levels of COX-2 or PGE2 seems to be more related 
to progression of colon carcinogenesis.  COX-2 expression increased with 
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advancement of colon cancer in AOM-treated rats (46) and sporadic human cancer 
(133).  Moreover, rofecoxib, a selective COX-2 inhibitor failed to inhibit ACF 
formation and only effectively reduced tumor progression (134).  In addition, age-
related differences were not observed in colonic COX-1 or COX-2 mRNA expression 
levels before or after AOM treatment (Section 3.3.2) whereas basal liver COX levels 
appeared to increase in older animals (data not shown).   
AOM has been widely used to induce colon tumors in preclinical models.  
We do not know why AOM-induced tumors mainly occur in the colon.  It is also still 
unclear what specific enzymes are involved in metabolic activation of AOM.  
Several studies suggested that metabolic activation of AOM is initiated by hepatic 
CYP2E1 (35).  However, administration of diallyl sulfide, a CYP2E1 inhibitor, 
increased AOM-induced formation of ACF in F344 rats (150).  Moreover, initial 
levels of colonic or liver DNA methyl adduct after the AOM treatment did not predict 
the differential susceptibility to colon tumors in inbred mice, and both susceptible and 
resistant mice strains had equivalent metabolic capacity estimated by production of 
O6-methyl guanine after the incubation of colon microsomes with AOM (151).  Also, 
several studies indicated that neither DNA repair enzyme activity or cell proliferation 
rates in the dimethylhydrazine (DMH)- or AOM-treated colons are modulated by 
dietary chemopreventive agents (152, 153) or aging (58, 119).  Dietary calcium 
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(152) or fish oil (153) did not affect either O6-alkyl guanine alkyltransferase activity 
or cell proliferation after DMH or AOM treatment in the same models where they 
showed chemopreventive activity and decreased levels of mutations or DNA adducts.  
Therefore, it was difficult to reason that any of AOM metabolism, repair enzyme 
activity, or cell proliferation was involved in age-related differences in curcumin 
chemopreventive efficacy.   
Apoptosis plays a role in maintaining the number of cells in normal mitotic 
tissues such as the colon.  Apoptosis is also an important mechanism to remove 
unwanted cells due to severe DNA damage (97).  Induction of apoptosis right after 
carcinogen treatment occurs in conjunction with activation of DNA repair systems 
(154), and therefore apoptosis may be an important mechanism to reduce mutation 
load and prevent initiation of cancer.  
Many different proteins regulate apoptosis.  Heat shock proteins (HSP) 
induced by stress may function at key regulatory points in the control of apoptosis 
(155).  Hsp70 has been most studied in terms of its transcriptional regulation and 
relationship with apoptosis.  Hsp70 is induced by exposure to various physiological 
and environmental stresses including elevated temperature, heavy metals, amino acid 
analogs, and oxidative stress (156).  It was also recently reported that occupational 
exposure to coke-oven emission, which is genotoxic, increases Hsp70 protein levels 
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in lympocytes in exposed workers (157).  Induced Hsp70 interacts with proteins 
damaged by stress and restores them to function properly allowing cells to maintain 
their function and survive (156).  On the other hand, overexpression of Hsp 70 
inhibits cell death, perhaps in spite of severe damage, and therefore increases the 
chance that damaged cells will grow into tumors.  Hsp70 protects cells from both 
stress-induced caspase-dependent and –independent apoptosis (101, 102).   
Transcription of Hsp70 is highly regulated through the transcriptional factor, 
heat shock factor 1 (HSF1), in eukaryotes (156).  Transcriptional activation and 
attenuation of Hsp70 in response to stress shows how strikingly these processes are 
regulated so that they rapidly respond to differing intensities and sources of stress and 
prevent overexpression.  Hsp70 induction also seems to be affected by maturation 
and/or the aging process (158-162).  There is accumulating evidence that 
transcriptional activation of Hsp70 by stress is delayed and/or decreased in older 
animals because of lower HSF1 binding activity to DNA (163).  
Interestingly, curcumin treatment induces Hsp70 under stress conditions 
(164) probably by increasing HSF1 binding activity to DNA, directly opposite to the 
behavior of HSF1 in older individuals.  Therefore, this study hypothesized that when 
AOM produces methylated adducts in association with DNA, RNA, and protein, it 
may induce Hsp70 and that curcumin may increase induction of Hsp70 by AOM 
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under this stress condition where transcription of Hsp70 is triggered.  This 
preliminary study was conducted to investigate whether AOM induces Hsp70 
expression and whether curcumin increases AOM-induced Hsp70 expression in the 
colon and the liver.   
 
4.2 Materials and Methods 
 
4.2.1 Experimental animals and diets  
Experimental animals were male 4-5 week old F344 rats.  Rats were 
randomly assigned into 8 groups (3 or 4 rats per group) depending on their 
experimental diets and time killed.  Among 31 rats, 8 rats were fed AIN-93 diet 
containing 0.6% curcumin and the rest were fed AIN-93 control diet.  Except for rats 
in the untreated control group (UNT), remainder (n = 4/group) was administered a 
single s.c. injection of AOM at the dose of 15 mg/kg body weight one week after 
being fed their experimental diets.  Rats in the control diet group (AIN) were killed 1, 
3, 7, 14, and 28 days after AOM injections.  Rats fed the curcumin diet (CUR) were 
killed 3 (AOM-3DAY) and 14 days (AOM-14DAY) after the AOM injections.  
Mucosa was scraped from colons for isolation of RNA and immunoassay.  Livers 
were also dissected and frozen using liquid nitrogen.  Collected tissues were stored 
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at –80 oC until analyzed.  
 
4.2.2 Gene expression levels using RT-PCR 
Total cellular RNA from colonic mucosa was extracted using TRIzol reagent 
(Invitrogen, Carlsbad, CA) and reverse transcribed into cDNA using Retroscript kit 
(Ambio Inc, Austin, TX) as described above (Section 2.2.3).  COX genes were 
amplified using mouse COX-1 or COX-2 gene-specific Relative RT-PCR Kit 
(Ambion Inc.).  The sequences for the specific oligonucleotides for Hsp70 were as 
previously described (165), and for p21 were as follows (sense: AGC AAA GTA TGC 
CGT CTC T, antisense: GAG TGC AAG ACA GCG ACA AG, Invitrogen).  An 
aliquot of cDNA was subjected to amplification for each gene using specific 
oligonucleotides.  Ribosomal gene 18S (498 bp) was used as an internal control.  
PCR reactions for mRNA amplification of each gene were carried out using the DNA 
engine (MJ Research, Waltham, MA).  The same thermocycling conditions were 
used as in COX-2 amplification (Section 2.2.3) except that the number of cycles was 
28 for Hsp70 and 26 for p21 and annealing temperatures were 59 and 60 oC, 
respectively.  The PCR products from multiplex reactions were quantified using 




4.2.3 Colonic PGE2 levels using EIA  
Colonic PGE2 levels were measured as described above (Section 3.2.5).  




4.3.1 Hsp70 mRNA expression in the colon  
Fig. 10 shows changes in Hsp70 mRNA expression in the colon with the time 
after AOM injections.  Colonic Hsp70 mRNA tended to decrease for 3 days after 
AOM injections and after that increased to the level of AOM-untreated controls (Day 
0).  Curcumin feeding did not significantly alter colonic Hsp70 mRNA levels as 























Figure 10. Time course of Hsp70 mRNA expression in relation to 18S mRNA 
expression in the colon of young rats following AOM injection (mean ± SE, n=3 or 4 
per group). Rats in Day 0 were AOM-untreated control. Rats in Day 1 were killed 1 
day after AOM injection vice versa. AIN: AIN-93 control diet, CUR: AIN-93 diet 
containing 0.6% curcumin 
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4.3.2 Hsp70 mRNA expression in the liver 
As shown in Fig. 11, liver Hsp70 mRNA levels were similar to basal levels 
(Day 0) for at least 7 days following AOM injection.  At Day 14 and 28 time points, 
Hsp70 mRNA levels were higher than levels at the Day 0.  Rats fed curcumin had 
similar Hsp70 mRNA levels when they were compared to control diet group at the 






















Figure 11. Time course of Hsp70 mRNA expression in relation to 18S mRNA 
expression in the liver of young rats following AOM injection (mean ± SE, n=3 or 4 
per group). Rats in Day 0 were AOM-untreated control. Rats in Day 1 were killed 1 
day after AOM injection vice versa. AIN: AIN-93 control diet, CUR: AIN-93 diet 
containing 0.6% curcumin 
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4.3.3 p21 mRNA expression in the colon 
Colonic mRNA levels of p21 fluctuated over the experimental time points 
and did not appear to be affected by AOM (Fig. 12).  At the Day 3 time point, p21 
mRNA levels of rats fed control diet were significantly higher (p < 0.05) than those of 
rats fed the curcumin diet.  However, p21 mRNA levels in curcumin-fed rats were 
only measured at one time point.  Due to fluctuation of transcriptional levels of p21 
with time in the control diet group, it is inconclusive whether curcumin affected p21 






















Figure 12. p21 mRNA expression in relation to 18 mRNA expression in the colonic 
mucosa of young rats following AOM injection (mean ± SE, n=3 or 4 per group). Rats 
in Day 0 were AOM-untreated control. Rats in Day 1 were killed 1 day after AOM 




4.3.4 COX-1 and COX-2 mRNA expression in the colon  
The levels of colonic COX-2 mRNA in AOM-treated rats (AOM-3DAY and 
AOM-14DAY) were similar to AOM-untreated rats (AOM-UNT) among groups fed 
the control diet (Fig. 13A).  In rats fed the control diet, COX-2 mRNA levels did not 
change with time up to 28 days after AOM injection (data not shown).  A significant 
effect of feeding of curcumin on the levels of colonic COX-2 mRNA was not evident 
3 days after AOM injection (AOM-3DAY).  However, 14 days after the AOM 
injection (AOM-14DAY), rats fed the curcumin diet had significantly higher (p < 
0.05) colonic COX-2 mRNA expression (Fig. 13, A) and PGE2 levels (Fig. 13, B) 
compared to rats fed the control diet.   
In contrast to COX-2 mRNA levels, AOM-treated rats (AOM-3DAY) in both 
diet groups had significantly lower (p < 0.05) COX-1 mRNA levels than UNT rats 
(Fig.13A).  Fourteen days after the AOM injection (AOM-14DAY), colonic COX-1 
levels returned to basal levels in both diet groups.  However, COX-1 mRNA levels 
recovered to a greater extent in curcumin-fed compared to control-fed rats, resulting 
in a significantly higher (p < 0.05) COX-1 mRNA expression in curcumin diet group 
compared to control diet group in AOM-3DAY (Fig. 13A).  There were no 
significant differences in the levels of liver COX-1 or COX-2 mRNA expression 































































Figure 13. Effect of curcumin on colonic arachidonic acid metabolism in young rats 
(mean ± SE, n=3 (UNT) or 4 rats/group). Transcriptional levels of COX-2 and COX-1 
in relation to 18S (A). PGE2 levels at AOM-14DAY (B). UNT: rats fed control diet 
(AIN) for one week and killed; AOM-3DAY: rats injected with AOM after feeding 
curcumin (CUR) or control diet (AIN) for one week and killed 3 days after the AOM 
injection; AOM-14DAY: rats injected with AOM after feeding of CUR or AIN for one 
week and killed 14 days after the AOM injection. There were no significant 




Hsp70 mRNA levels in the colon were not elevated after AOM injection.  
Rats fed curcumin have not increased colonic Hsp70 mRNA levels compared to rats 
fed the control diet.  These results were unexpected as it was hypothesized that AOM 
would induce Hsp70 expression and that this induction would be further enhanced by 
curcumin.  One possible explanation is that Hsp70 induction occurred before the 24 
hour time point.  If AOM can induce the heat shock response, the time course of 
Hsp70 expression may resemble, but be slightly earlier than, the time course of 
apoptosis induction.  Previous studies show that the apoptotic incidence reached 
maximum levels at 6~8 hours after AOM injection (153) and cellular rate of apoptosis 
was almost back to basal levels 3 days after AOM injection in young rats (166).  In 
our study, the transcriptional level of Hsp70 was lower after AOM injection, although 
this was not significant, possibly because there were only 3 or 4 rats per group.  
Hsp70 mRNA levels are regulated by Hsp70 protein by a negative feedback 
mechanism (167).  It is possible that Hsp70 protein expression was induced by the 
AOM injection and was present prior to apoptosis induction (i.e. earlier than the peak 
of apoptosis, 8 hours after AOM injection).  If that occurred, then Hsp70 mRNA may 
be already attenuated by high levels of Hsp70 protein at 24 hours following AOM 
injection, which was the time it was measured.   
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Another possible explanation of the lack of effect of AOM and curcumin on 
Hsp70 may be involvement of other potential Hsp70 effectors.  CO2 was used for 
euthanasia of rats and variation in the time for rats to succumb to CO2 might be 
reflected in the results as transcription of Hsp70 can be induced by hypoxic conditions 
(168).  If this is the case, Hsp70 mRNA levels of rats untreated with AOM do not 
represent basal levels and the effect of AOM and curcumin on Hsp70 expression level 
cannot be detected.  Also, AOM untreated control animals were not included at each 
time point, therefore the effect of the developmental stage of rats on Hsp70 expression 
cannot be assessed, making it difficult to interpret the increase of Hsp70 
transcriptional levels at 7 days after AOM injection in the liver.   
Transcriptional levels of p21 were measured in the colon in order to estimate 
the extent of AOM-induced DNA damage, as p21 levels are known to increase in 
response to DNA damage.  However, our study did not show that AOM affects p21 
mRNA expression.  Aizu et al. (169) suggested that p21 expression was not affected 
by AOM in the mouse colon both at transcriptional and translational levels due to 
down-regulation of p300, the transcriptional co-activator of p53 by AOM.  Their 
study showed that AOM increased both transcriptional and translational levels of p21 
and other p53-regulated genes such as Bax and Gadd45 3 hours after AOM injection 
in the liver whereas AOM did not affect expression of those genes in the colon – 
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transcriptional levels were not changed when measured at 0, 3, 6, 24 and 48 hours 
after AOM injection.  Therefore, in this study where AOM was used as a DNA 
damaging agent, p21 mRNA levels may not be a good indicator of DNA damage with 
time.   
In the previous study (Section 3.3.1), feeding 0.6% curcumin did not inhibit 
either COX mRNA expression or PGE2 production in the colon, but rather increased 
COX-2 mRNA levels.  This lack of inhibitory effect of dietary curcumin on 
arachidonic acid metabolism might be the cause of failure of colonic 
chemoprevention by curcumin in middle-aged rats.  However, as reviewed above, it 
is also now questionable whether inhibition of arachidonic acid metabolism is an 
important chemopreventive mechanism in the early stage of colon carcinogenesis.  
Based on recent reports, another possibility is that the increase of COX-2 mRNA 
expression in curcumin-fed rats was a biologically required event.  Tanaka et al. 
(138) reported that COX-2 mRNA levels were up-regulated in the stomach shortly 
after the administration of a selective COX-1 inhibitor but not after a selective COX-2 
inhibitor.  A selective COX-1 inhibitor decreased PGE2 content in the stomach 
mucosa 2 hours after administration of the inhibitor however, levels were being 
recovered by 8 hours due to an increased expression of COX-2 (138).  This suggests 
a compensatory role of COX-1 and COX-2 in maintaining the PGE2 content in 
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gastrointestinal mucosa.  We investigated if the increased COX-2 mRNA in the 
curcumin diet group was associated with reduced COX-1 expression.  Feeding 0.6% 
curcumin to young rats did not affect COX-2 mRNA expression 3 days after AOM 
treatment (Fig. 13A).  However, similar to the previous result in middle-aged rats, 
significantly higher levels of COX-2 mRNA were measured 14 days after AOM 
treatment in the colonic mucosa of young rats fed curcumin compared to rats fed the 
control diet.  Colonic levels of PGE2 were also significantly higher in young rats fed 
the curcumin diet.  This was not consistent with a previous study by Rao et al. (114) 
showing a significant reduction in colonic production of PGE2 after feeding young 
rats a 0.2 % curcumin diet for 19 days.  However, in their study, COX activity was 
measured as the in vitro production rate of prostaglandins including PGE2 by colonic 
microsomal proteins in the presence of sufficiently added arachidonic acid whereas in 
our study, endogenous PGE2 levels were measured in the colonic homogenates.  
Recent reports suggest that phospholipase activity is reduced in both AOM-induced 
colonic ACF and tumors, reducing available free arachidonic acid (170).  Therefore, 
in vitro measurement of PGE2 in the previous study might not properly reflect the 
production rate of endogenous prostaglandins in vivo if AOM-induced carcinogenesis 
reduces available arachidonic acid.   
The increase of COX-2 and PGE2 in young rats fed the curcumin diet seems 
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to be related with decreased COX-1 mRNA levels in the colon, shortly after the AOM 
injection.  The elevation of COX-2 mRNA expression at 14 days was preceded by 
the reduction in COX-1 mRNA levels 3 days after AOM injection (Fig. 13A).   
Although one cannot directly compare two studies, which differ in age of animals and 
duration of study, we speculated that the higher COX-2 mRNA levels observed 
previously at the stage of ACF formation in middle-aged rats fed curcumin diet 
(Section 3.3.1) might be also due to a response to decreased COX-1 mRNA levels by 
AOM treatment.  The previous study (Section 3.3.2) demonstrated that the inhibitory 
effect of AOM on colonic COX-1 mRNA was not limited to young animals.  
Therefore, aging does not appear to alter the effect of curcumin on colonic COX-2 
mRNA expression in either AOM-treated or untreated rats.    
In conclusion, transcriptional levels of Hsp70 were not significantly affected 
by either AOM treatment or curcumin probably because transcriptional induction of 
Hsp70 occurred earlier than our first time of measurement at 24 hours.  p21 also did 
not appear to be significantly affected by AOM treatment.  Rats fed curcumin had 
significantly increased transcriptional levels of COX-2 and PGE2 levels in the colon 
of young rats, which probably was a compensatory mechanism in response to initial 
reduced COX-1 mRNA expression.  Therefore, this study and the previous study in 
Chapter 3 together suggest that the effect of curcumin on arachidonic acid metabolism 
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in the colon may not contribute to the age-related difference in the chemopreventive 
activity of curcumin. 
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Chapter 5. Effect of aging on AOM-induced apoptosis in the 
colon of rats 
 
5.1 Introduction  
Apoptosis is genetically programmed cell death characterized by a highly 
ordered decomposition of DNA and proteins (171).  Regulation of cellular apoptosis 
is important for tissue homeostasis.  Inappropriate activation of apoptosis may cause 
loss of constituent cells and result in tissue dysfunction, or tissue may retain cells 
prone to mutations and potentially develop neoplasia, especially if cells are highly 
resistant to apoptotic stimuli.  The aging process might be derived by an altered 
apoptotic response (172, 173).  It is becoming evident that deregulation of apoptosis 
may cause age-related diseases including neurodegenerative diseases, osteoarthritis, 
cardiovascular diseases, and cancer (173, 174).  
It is generally accepted that cellular dysfunction is related with loss of cells 
due to a high incidence of apoptosis in some post-mitotic tissues like neurons and 
muscles (174).  However, how the aging process affects the regulation of apoptosis 
in mitotic tissues has been understudied.  In the normal colon, age does not appear to 
significantly affect either cell proliferation or apoptosis (109).  Lee et al. (109) 
speculated that age-related differences in apoptosis may not be sufficient enough to 
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detect, as apoptosis rarely occurs both in young and old normal colonic epithelium.  
Apoptosis may more likely take place upon exposure to toxic substances such as 
carcinogens, and cellular control of apoptosis in response to carcinogens may 
significantly affect not only carcinogenesis but also cellular function in the colon.  
Azoxymethane (AOM) has been widely used to induce colon cancer in 
rodents.  AOM is metabolized to highly reactive methyldiazonium, which can bind 
to DNA and cause mutations (35).  In mediating cellular responses to the DNA 
damage, transcriptional factors, p53, AP-1 (activator protein-1), and nuclear factor 
kappa B (NF-κB), play significant roles (175).  In contrast to the p53 tumor 
suppressor, which induces cell cycle arrest and apoptosis, activation of NF-κB 
promotes resistance to programmed cell death (176).  Paradoxically, many DNA 
damaging agents induce activation of both p53 as well as NF-κB (176). 
In most type of cells, inactive NF-κB is sequestered in cytoplasm through 
interaction with the inhibitory proteins, IκBs (175).  Upon exposure to stimuli such 
as cytokines, reactive oxygen species, and genotoxic drugs, IκBs are phosphorylated 
by their kinase, IKK, and rapidly degraded, allowing NF-κB to be released and 
translocate to the nucleus where it subsequently activates its target genes.  Many of 
NF-κB-regulated genes are anti-apoptotic and include the protein families of Bcl-2 
and inhibitors of apoptosis (IAP).  IAP suppresses apoptosis by direct inhibition of 
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proteolytic caspases.  X-chromosome linked IAP (XIAP) is the most potent inhibitor 
of apoptosis but its regulation by NF-κB seems to be limited to specific cell types 
(176).  Although IAP-1 and IAP-2 have reduced ability to inhibit apoptosis 
compared to XIAP, their induction in response to activation of NF-κB has been 
observed in various cells (176, 177).  It is well known that activation of NF-κB 
induces transcriptional activation of Bcl-xL in many different types of cells.  Recent 
studies also suggested the involvement of Bcl-2 in the anti-apoptotic activity of NF-
κB (175, 176).  It is well understood that high expression of Bcl-xL and Bcl-2 
inhibits apoptosis through the suppression of the release of cytochrome c from 
mitochondria (178, 179).   
On the other hand, p53 activity seems to be inhibited in the AOM-treated 
colon.  Shortly after the AOM injection to mice, p53-regulated genes were not 
induced in the colon in contrast to rapid induction of p53-responsive genes including 
p21 and Bax in the liver (169).  In addition, Wu et al. (23) reported that cytosolic 
wild type (wt) p53, which is stable and inactive, was increased whereas active 
mitochondrial wt p53 decreased in the colon after AOM treatment although levels of 
wt p53 mRNA and total proteins were not inhibited by AOM.  Therefore, activation 




AOM induces apoptosis in the colonic epithelium within several hours after 
AOM injection in young animals (166).  However, the time course of apoptosis upon 
exposure to AOM in older animals has not been studied.  This study investigated the 
effect of aging on the regulation of apoptosis in response to an acute exposure to 
AOM.  In this study, the time course of apoptotic response in different ages of 
animals was investigated to determine whether older animals respond excessively or 
bluntly to the exposure of colonic cytotoxicants compared to young animals.  Also, 
NF-κB-regulated genes, Bcl-2, Bcl-xL, and IAP-2 were examined to assess whether 
differences in apoptosis induction by age involves regulation of those genes. 
 
5.2 Materials and Methods 
 
5.2.1 Experimental animals and diets 
Experimental animals were young (6 weeks), middle-aged (12 months), and 
old (22 months) male F344 rats purchased from the colony at the National Institute of 
Aging (Bethesda, MD).  The rats were fed the AIN-93 diet for 1 week after 
acclimation to lab conditions.  All the rats except 6 rats per age group were given 
single s.c. injection of AOM (Sigma, St. Louis, MO) at the dose of 15 mg/kg.  Six 
rats per age group were killed at four different time points, 4, 8, 16, and 24 hours after 
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AOM injection.  The zero hour control was injected with saline right before they 
were killed as a sham control.  Colons were collected after flushing with cold saline.  
Two cm of colon tissue from the distal end were fixed in 10% formaldehyde for 
immunohistochemistry and the rest of the colon was scraped to collect epithelial 
mucosa.  One half of the mucosa from each rat was fixed in RNAlater (Ambion Inc, 
Texas, AU) for RNA isolation and the other half was frozen on liquid N2 for protein 
analysis.  Tissues were then frozen at –80 oC until analyzed. 
 
5.2.2 Apoptosis 
Paraffin-embedded colon pieces were subjected to immunohistochemistry 
using ApopTag Peroxidase kits (ApopTag 700, Chemicon International, Inc., 
Temecula, CA) according to the manufacture’s instructions, and apoptotic indices 
were determined by counting the total number of stained cells per crypt.  Briefly, 
DNA 3’-OH ends were labeled with oligonucleotides containing digoxigenin 
conjugate by terminal deoxynucleotidyl transferase.  Labeled cells were detected by 
anti-digoxigene conjugated with peroxidase reporter and subsequent reaction with 





5.2.3 Transcriptional levels of Bcl-2, Bcl-xL, and IAP-2 using RT-PCR 
Total RNA was extracted from colon mucosa and reverse transcribed to 
cDNA as described (Section 2.2.3).  An aliquot of cDNA was subjected to RT-PCR 
for each gene using specific oligonucleotides for Bcl-2 (180), Bcl-xL (181), and IAP-
2 (sense: AAA TGC TGA CCC TCC AG, antisense: AAA TGC TGA CCC TCC ACT 
TG, Invitrogen).  The DNA engine (MJ Research, Waltham, MA) was used for 
mRNA amplification of each gene.  Thermocycling conditions were used as follows: 
one 2-min cycle at 94 oC, 30 ( IAP-2 and Bcl-Xl) or 32 (Bcl-2) cycles of denaturation 
for 30 s at 92 oC , annealing for 30 s at 57 oC (Bcl-xL) or 60 oC (IAP-2 and Bcl-2), 
and extension for 1 min at 72 oC, and a final extension for 5 min at 72 oC.  
Ribosomal 18S was used as an internal control and the PCR products from multiplex 
reactions were analyzed using DNA 500 LabChip® and Agilent 2100 bioanalyzer as 
previously described (Section 2.2.3).  
 
5.2.4 Data analysis 
This study was a two factorial (age × time) design.  Two-way analysis of 
variance (ANOVA) was conducted using SAS software (9.1, SAS Institute Inc, Cary, 
NC) to investigate the effect of age, time and their interaction on apoptosis and 





5.3.1 Apoptosis  
An apoptotic peak in the colon was reached 8 hours after AOM injection and 
after that apoptotic incidence decreased with time but was still elevated 24 hours after 
the carcinogen treatment compared to basal levels in all age groups (Fig. 14).  Older 
animals had significantly higher apoptotic indices (total stained cells/crypt) at 8 (p < 
0.05) and 16 hours (p < 0.07) after AOM injection, compared to young animals.  
When two-way ANOVA was conducted, there were significant differences in effects 



























Figure 14. Time course of apoptosis indices in the distal colon of young, middle aged 
and old rats after being treated with AOM (mean ± SE, n=5 or 6/group). Apoptotic 
index was generated by counting total stained cells per crypt. Except for 24 hour point 
in young rats, apoptotic indices were higher (p < 0.05) at 8, 16, and 24 hour points 
compared to 0 or 4 hour point in each age group. Middle-aged and old rats (lower 
panel, left) had significantly higher (p < 0.05) apoptotic indices compared to young 
rats (lower panel, right) at 8 hour time point. Two-way ANOVA indicated significant 
effects of age, time, and interaction of age and time.  
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5.3.2 Transcriptional levels of Bcl-2, Bcl-xL, and IAP-2  
Changes in colonic transcriptional levels of Bcl-2, Bcl-xL and IAP-2 with 
time after AOM injections showed a similar trend in each age group – mRNA levels 
of genes were lowered after carcinogen treatment in young and old rats whereas in 
middle-aged rats, they were unchanged following AOM injections (Fig. 15).  Two-
way ANOVA showed that there was a significant interaction of age and time in Bcl-xL 
and Bcl-2 mRNA levels.  
Young rats showed the most apparent change of mRNA expression levels of 
the genes after AOM treatment.  In young rats, transcriptional levels of all of the 
genes, Bcl-xL, IAP-2, and Bcl-2, were significantly reduced (p < 0.05) 24 hours after 
the AOM treatment compared to 0 hour control (Fig. 15).  In old group, Bcl-xL and 
IAP-2, but not Bcl-2 mRNA levels, were significantly decreased following AOM 
treatment.  There were no significant changes in transcriptional levels of Bcl-xL, 



















































Figure 15. Changes in transcriptional levels of Bcl-xL, IAP-2, and Bcl-2 in relation to 
18S in the colon of three different ages of rats 0, 8 or 24 hours after AOM injection 
(mean ± SE, n=5 or 6/group). * represents significant differences (p < 0.05) compared 
to 0 hour control in each age group by ANOVA.  
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5.4 Discussion  
Apoptosis is a critical mechanism in maintaining tissue homeostasis.  Two 
apoptotic pathways are known.  One is the external pathway where death-receptors 
are involved and the other is the mitochondrial-dependent pathway, called the internal 
pathway.  Cellular apoptotic events are highly regulated by many proteins whose 
expressions are controlled by many different signaling pathways as described above 
(Section 1.6).  The regulation of apoptosis varies by stimuli and intensity of 
apoptosis, and depends on cell types.  Even more complicated, the two apoptotic 
pathways interact and induction of one apoptotic pathway requires amplification of 
apoptotic signaling by the other pathway (100).  
Deregulation of apoptosis seems to contribute to the aging phenotype.  In 
post-mitotic tissues, apoptosis increases with age and causes loss of tissue structure 
and function due to loss of cells as seen in muscle atrophy, sarcopenia, and 
neurodegenerative diseases (174, 182, 183).  However, it is largely unknown how 
aging contributes to the regulation of apoptosis in mitotic tissues including the colon.  
The current study confirmed previous results that basal levels of apoptosis were 
similar among different age groups (109) and that maximum levels of apoptosis were 
reached 8 hours after the AOM injection in young rats (166).  Aging did not alter the 
time at which apoptosis reaches a peak (Fig. 14).  However, the levels of AOM-
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induced apoptosis at the peak were higher in older animals compared to young.  
Therefore, this study showed that apoptosis increases with age upon exposure to a 
genotoxic agent in the mitotic tissue, the colon, as demonstrated in many post-mitotic 
tissues. 
Upon exposure to DNA damaging agents, apoptosis functions to remove 
damaged DNA and reduce mutation load in tissues (184, 185).  Therefore, apoptosis 
is a critical mechanism to prevent initiation of cancer.  In the first study (Chapter 2), 
the development of ACF after AOM treatment was lower in middle-aged and old 
compared to young rats.  Higher incidence of apoptosis immediately after the AOM 
treatment in older animals may inhibit the initiation of colon cancer and therefore 
explain the reduced development of colonic preneoplastic lesions, ACF.  
On the other hand, high incidence of apoptosis may eventually cause loss of 
functional cells in the colon.  Apoptosis depletes the stem cell pools that replenish 
renewable tissues (186, 187).  Notably, the majority of AOM-induced programmed 
cell death occurred in the bottom of crypts in both young and old animals (Fig. 14).  
The fact that AOM-induced apoptosis targets stem cells was also previously observed 
(154).  By contrast, in the normal colon, apoptotic cells are often found in the upper 
portions of the crypts where highly differentiated cells reside and are exfoliated into 
the lumen for excretion (154).  How this high incidence of apoptosis contributes to 
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the aging phenotype in the colon needs further study.  However, it might be 
reasonable to assume that a high incidence of apoptosis in the colon of older rats may 
potentially contribute to loss of structure and function due to loss of functional cells as 
demonstrated in post-mitotic tissues.  It should be also noted that destruction of 
tissue structure can deregulate cell proliferation, differentiation and apoptosis (188-
190) and that modification of tissue structure can actually initiate cancer (191).   
Another possible mechanism by which over-activation of apoptosis may 
increase the cancer development is the stimulation of cell proliferation to compensate 
for loss of cells, thereby, potentially providing more chances to establish the 
mutations by replication.  In fact, basal levels of cell proliferation determined by 
proliferating cell nuclear antigen (PCNA) were slightly but significantly higher in 
older rats compared to young rats (Chapter 6).  A previous study (166) showed that 
three days after AOM single injection, cell proliferation rate was significantly 
elevated compared to basal levels in young rats, probably in order to replenish lost 
cells.  Cell proliferation rate was significantly reduced 16 hours after AOM injection 
compared to basal levels only in old rats whereas proliferation rate was not altered in 
either young or middle-aged rats (Chapter 6).  If loss of cells due to apoptosis 
increases cell proliferation even higher than basal levels in old rats as in young rats  
(166), cell proliferation would dramatically rise in old animals probably much higher 
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than young.  A high incidence of cell proliferation is considered to increase risk of 
cancer development due to the increased chance of a mutation leading to 
preneoplastic lesions.  Repeated exposures to genotoxic agents may have substantial 
impact on individuals highly susceptible to apoptotic stimuli.  In the short term, high 
incidence of apoptosis in response to AOM in older animals has a beneficial effect in 
prevention of initiation of colon cancer.  In the long term, however, the high 
susceptibility to induced apoptosis may potentially contribute to the aged phenotype 
and increased cancer incidence due to loss of tissue structure and deregulation of cell 
proliferation, providing an environment more conducive to cancer initiation and 
promotion.  
In this study, changes in the expression of NF-κB-regulated genes following 
AOM treatment were examined.  Bcl-2, Bcl-xL, and IAP-2 transcriptional levels 
were all similarly affected by AOM treatment in three different aged rats.  
Interestingly, except for Bcl-2, these three genes were transcriptionally less expressed 
24 hours after AOM injection compared to 0 hour control in young and old animals 
(Fig. 15).  On the contrary, in middle-aged rats, none of these genes were 
significantly reduced after AOM injection.  The protein products of these genes 
inhibit apoptosis.  Assuming that the change in messages of Bcl-2, Bcl-xL, and IAP-
2 are translated to protein levels, inhibitors of apoptosis would be decreased in the 
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colon of young and old rats and increase sensitivity to apoptosis, in contrast to no 
changes in the colon of middle-aged rats.  The change in transcriptional expression 
levels of those genes did not appear to relate with age-related differences in apoptosis 
induction, as if this were the case, the lowest levels of apoptosis should have been 
observed in middle-aged rats.   
Bcl-2, Bcl-xL, and IAP-2 proteins seem to play critical roles in inhibiting the 
mitochondrial-dependent pathway.  IAP family inhibits caspase-9 and hence the 
cleavage of pro-caspase-3 to the active form whereas no apparent effect of IAPs was 
reported in activation of caspase-3 by caspase-8 (192, 193).  Bcl-2 and Bcl-xL 
inhibit cytochrome c release from mitochondria and therefore suppress apoptosis 
mediated by the mitochondrial-dependent pathway (194).  Whether high expression 
of Bcl-2 or Bcl-xL also has an inhibitory effect on death receptor-mediated pathway 
of apoptosis is controversial (100).  This seems to depend on the type of cells (100).  
A certain type of cells is resistant to apoptosis induced by death ligands.  This type 
of cells has low death receptor levels, is resistant to cross linking of receptors, or 
possibly expresses inhibitory decoy receptors.  Also, this type of cells has high levels 
of anti-apoptotic proteins like IAPs and require the release of mitochondrial 
Smac/DIABLO, which sequester IAPs in order to activate caspase-9 and caspase-3.  
This release of Smac/DIABLO from mitochondria is inhibited by Bcl-2 family.  
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Therefore, in this type of cells, Bcl-2 or Bcl-xL has inhibitory effect on death 
receptor-mediated apoptosis as well.  It should be confirmed that transcriptional 
levels of Bcl-2, Bcl-xL and IAP-2 were translated to protein levels.  The 
mitochondrial-independent pathway, which is not affected by IAPs or Bcl-2/Bcl-xL, 
might be responsible for the age-related differences in AOM-induced apoptosis. 
Many chemicals that induce DNA damage are known to induce apoptosis 
through the mitochondrial-dependent pathway or both internal and external pathways.  
It is not well understood how AOM induces apoptosis in the colon.  Several studies 
also reported that production of cytokines, including TNF-α and IL-6, is elevated in 
AOM-treated colon (170, 195, 196) although it is not clear whether levels of 
cytokines are increased directly by AOM treatment or during progression of 
carcinogenesis.  Interestingly, it is well established that production of TNF-α and IL-
6 increases in older individuals (197).  Moreover, old subjects not only produce 
higher TNF-α but also are more susceptible to TNF-α-induced apoptosis compared to 
younger individuals (197).  It would be interesting to investigate if older rats 
increase colonic production of cytokines including TNF-α or IL-6 in response to 
AOM exposure or are more sensitive to apoptosis induced by those cytokines. 
In summary, this study showed that the colons of older animals are more 
susceptible to AOM-induced apoptosis and this age-related difference in the incidence 
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of apoptosis is likely not related with NF-κB activity.  Further study will be required 
to identify the apoptotic pathway that AOM induces and to understand the biological 
significance of high susceptibility of older animals to apoptosis upon an exposure to a 
colon carcinogen.  
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Chapter 6. Effect of aging on colonic apoptosis induced by 
AOM and curcumin 
 
6.1 Introduction 
Middle-aged rats are resistant to inhibition of colonic ACF development by 
dietary curcumin (Chapter 2).  ACF represent a stage of initiation and early 
promotion in colon carcinogenesis.  In the early stages of carcinogenesis, the 
dynamics of carcinogen metabolism, repair of DNA mutation, cell proliferation and 
apoptosis determine the mutation load in the tissue and the initiation of carcinogenesis.  
The induction of apoptosis may be an important mechanism in the inhibition of AOM-
initiated colon carcinogenesis.  Shortly after the AOM injection, p53-regulated genes 
were not significantly induced in the colon of mice whereas they were markedly 
enhanced in the liver (169), indicating suppression of apoptosis or cell cycle arrest by 
AOM treatment in the colon.  Also, the efficacy of chemoprevention appears to be 
related with the ability of chemopreventive agents to induce apoptosis.  Samaha et al. 
(198) reported that the high tumor incidence (number of rats bearing tumors) was 
correlated with a lower apoptotic index when they used different chemopreventive 
agents.  Moreover, studies that investigated the chemopreventive activity of pectin 
and fish oil in AOM-induced colon cancer suggest that the chemopreventive effect of 
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diet may be due to the increase of apoptosis not the decrease of cell proliferation at all 
stages of carcinogenesis, initiation, promotion, and progression (33, 153, 199).  
The induction of apoptosis by curcumin and potential apoptotic pathways that 
curcumin may mediate has been extensively studied (84, 95, 96, 104, 105, 200, 201).  
Most were conducted in vitro and the apoptotic pathways affected by curcumin varied 
depending on cell line types and concentrations of curcumin used.  However, many 
studies suggest that curcumin induces apoptosis through the mitochondrial-dependent 
pathway.  In addition, a recent study (202) showed that young rats fed curcumin had 
higher active caspase-9 expression levels, indicating that curcumin-induced apoptosis 
is mediated by the mitochondrial-dependent pathway.  
Based on previous studies above, the resistance of middle-aged rats to 
curcumin chemoprevention (Chapter 2) may be due to the failure of curcumin to 
enhance apoptosis in middle-aged rats.  One of the potential mediators may be 
Hsp70 in the colon as described previously (Section 4.1).  However, the preliminary 
study (Chapter 4) investigating the time course of Hsp70 mRNA expression after 
AOM injection did not provide conclusive results.  It would be relevant to first 
determine whether age affects curcumin-induced apoptosis rather than search for 
responsible modulators.  Regulation of apoptosis is a significant event in both the 
aging process and cancer prevention as reviewed above.  Moreover, the study 
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described in Chapter 5 showed significant age-related differences in AOM-induced 
apoptosis.  
Therefore, this study investigated whether age affects curcumin-induced 
apoptosis and whether it is related to the resistance to chemopreventive activity of 
curcumin in middle-aged animals.  In this study, the time course of Hsp70 
expression following AOM injection was also examined to determine if AOM induces 
Hsp70 mRNA expression, and if the induction of Hsp70 has a regulatory role in 
curcumin-induced apoptosis.  Additionally, the activity of caspase-9 was assessed to 
investigate if curcumin-induced apoptosis is mediated through the mitochondrial-
dependent pathway. 
 
6.2 Materials and Methods 
 
6.2.1 Experimental animals and diets 
Male F344 rats at the ages of 6 weeks, 12 months, and 22 months were 
purchased from the same colony described above (Section 5.2.1).  Rats were 
randomly allocated into either AIN or CUR diet groups.  All the rats were injected 
with AOM at the dose of 15 mg/kg body weight after 1 week on their diets.  Eight 
and sixteen hours after the AOM single injection, rats were killed.  Rats in the 0 hour 
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control group were injected with saline right before they were killed.  These rats 
represented basal levels.  A 2 cm colon piece from the mid point towards the distal 
colon, and one from the distal end were fixed in 10% formaldehyde for 
immunohistochemisty and the rest of colon was scraped for mucosa and stored for 
RNA and protein isolation as described (Section 5.2.1).  
 
6.2.2 Apoptosis 
Incidence of apoptosis was assessed by immunohistochemical staining using 
ApopTag Peroxidase Kits (Chemicon International, Inc., Temecula, CA) and apoptotic 
indices of total stained cells per crypt were generated as described (Section 5.2.2).  
Two sections (one from distal and the other from middle of the colon) of each colon 
were used for apoptosis to determine if results differed with the region of the colon. 
 
6.2.3 Cell proliferation 
Paraffin-embedded colons from two locations (one from distal and the other 
from middle of the colon) were sectioned and subjected to immunohistochemical 
staining for PCNA.  Tissue sections were incubated with primary antibodies against 
PCNA (predilute, Zymed Laboratories, South San Francisco, CA) for one hour at 
room temperature.  Histostatin-Plus kits (DAB, Broad Spectrum, Zymed) were used 
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to successively conjugate primary antibodies with biotinylated secondary antibodies, 
streptavidin-peroxidase conjugates and diaminobenzidine (DAB) substrates.   
Computer-Assisted Image Analysis was employed to quantitatively measure 
immunohistochemically stained PCNA.  Each stained slide was viewed at 100X with 
a Nikon Eclipse microscope mounted with a high-resolution camera.  Images were 
obtained from two locations of each section and a mean labeling index was calculated 
as the percentage of the positive nuclear-stained area in the total nuclear area using a 
Image-Pro Plus 6.0 image analysis software (Media Cybernetics, Silver Spring, MD).  
Only complete crypts with a clear opening to the lumen were selected for analysis.  
 
6.2.4 Transcriptional levels of Hsp70 by RT-PCR 
Hsp70 mRNA levels were measured by RT-PCR and the ratio of Hsp70 to 
18S was determined as previously described (Section 4.2.2).  
 
6.2.5 Caspase-9 protein levels by Western blotting 
Frozen colon mucosa samples were lysed with T-PER tissue protein 
extraction reagent (Pierce Biotechnology, Inc., Rockford, IL) containing protease 
inhibitors (Halt protease inhibitor cocktail, Pierce Biotechnology).  Tissue 
homogenates were centrifuged at 10,000 g for 5 min at 4 oC.  Aliquots of tissue 
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supernatant were mixed with sample loading buffer (50 Mm Tris buffer pH 6.8, 10% 
glycerol, 2% SDS, 5% β-mercaptoethanol, and 0.02% bromophenol blue) and 
denatured at 95 oC for 5 min.  Denatured proteins were loaded onto 10-20% gradient 
Novex® Tris-Glycine gels (Invitrogen, Carlsbad, CA).  After electrophoresis, 
proteins were transferred onto nitrocellulose membranes and probed with caspase-9 
antibody (MBL International, Woburn, MA).  The Western blot was visualized using 
Super Signal West Pico Chemiluminescent Substrate (Pierce Biotechnology).  The 
densitometry of the bands corresponding to the molecular size of active caspase-9 (35 
kD) and procaspase-9 (45 Kd) were quantified using Image J software (1.35g, NIH) 
and the ratio of active caspase-9 to procapase-9 was generated for each rat.  There 
was no difference among samples in intensity of bands of β-actin used as a loading 
control.  Protein concentration of tissue lysates was measured using Coomassie Plus 
protein assay kit (Pierce Biotechnology).  
 
6.2.6 Data analysis  
Two-way analysis of variance (ANOVA) using SAS software (9.1, SAS 
Institute Inc, Cary, NC) was performed to examine the effect of diet, time, and their 
interaction on the ratio of Hsp70 to 18S mRNA levels and the ratio of active caspase-
9 to procaspase-9 in each age group.  Two-way ANOVA was also conducted to 
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determine if there were significant effects of age, diet, and their interaction on 
apoptotic index in each time after the AOM injection due to high variability of values 





There was a significant interaction effect (p < 0.05) of age and diet at all time 
points.  Curcumin-fed young and old rats showed significantly higher basal levels (0 
hour) of apoptosis in the colon in contrast to no effect of curcumin in middle-aged rats 
(Fig. 16).  Dietary curcumin also enhanced AOM-induced levels of apoptosis in 
young and old rats, at 8 and 16 hours, respectively, compared to their control diet 
counterparts whereas middle-aged rats had similar levels of apoptosis in both diet 
groups in all time points (Fig. 16).  Results from the middle colon were similar, but 









































Figure 16. Effect of curcumin on levels of basal and AOM-induced apoptosis in the 
distal colon of three different aged rats (mean ± SE, n=5 or 6/group). AIN is the group 
fed the AIN-93 control diet and CUR is the group fed the AIN-93 diet containing 
0.6% curcumin. Apoptosis was detected by immunohistochemical staining 0, 8, and 
16 hours after AOM injection. Apoptotic indices were generated by counting total 
number of stained cells per crypt. * represents significant differences (p < 0.05) 
between AIN and CUR at each time point and each age group by ANOVA.   
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6.3.2 Cell proliferation 
Changes of cell proliferation rate in distal colon expressed as PCNA labeling 
index is shown in Table 3.  In control diet group, basal levels (0 hour) of PCNA 
labeling indices were significantly higher (p < 0.05) in middle-aged and old rats 
compared to young rats in the distal colon.  Feeding curcumin did not significantly 
affect basal levels of cell proliferation in any ages of rats.  Carcinogen treatment 
significantly reduced (p < 0.05) the proliferation rate in all ages of rats fed curcumin.  
In the control diet group, only old rats had a significantly reduced cell proliferation 
rate following AOM injection, but this was still higher than in rats fed the curcumin 
diet.  Therefore, after carcinogen treatment, rats fed the curcumin diet had 
significantly lower (p < 0.05) levels of PCNA staining compared to their control diet 
counterparts in all three ages.  There were no significant changes by age, diet, or 
time after AOM treatment in the middle colon (data not shown).  
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Table 3. PCNA labeling index (%) in distal colons of three different aged rats before 
and after AOM injection 
Timea)        Age 
Dietb)
Young Middle-aged Old 
AIN 13.6 ± 1.79c) 22.6 ± 3.00d)  28.8 ± 3.93d)
0 hour 
CUR 12.8 ± 3.31 17.1 ± 3.23 20.5 ± 4.09 
AIN 13.3 ± 1.86 15.4 ± 1.64 14.7 ± 3.22f)
16 hour 
CUR  6.9 ± 1.59e)  5.0 ± 0.82e),f)  6.2 ± 1.43e),f)
a) Rats were killed 0 or 16 hours after AOM injection 
b) AIN is AIN-93 control diet and CUR is AIN-93 diet containing 0.6% curcumin 
c) PCNA labeling index was calculated by percentage of nuclear-stained area of the 
total nuclear area, mean ± SE (n=5 or 6 per group). Data values were log transformed 
due to large difference in variance among different groups for ANOVA.  
d)Significant difference (p < 0.05) among different age groups at each time point and 
each diet group by ANOVA  
e)Significant difference (p < 0.05) between diet groups at each time point and each age 
group by ANOVA  
f)Significant difference (p < 0.05) between time points at each age and each diet group 
by ANOVA  
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6.3.3 Hsp70 mRNA levels  
In young rats, Hsp70 mRNA levels were increased after AOM injections in 
the control diet group.  Young rats fed the control diet had significantly higher (p < 
0.05) Hsp70 levels 16 hours after AOM treatment compared to basal levels (Fig. 17).  
This elevated level of Hsp70 mRNA in young rats was significantly lowered in rats 
fed curcumin (Fig. 17).  However, there were no significant differences (p > 0.05) by 
either AOM treatment or diet in old animals (Fig. 17) and results similar to old were 























Figure 17. Changes in Hsp70 transcriptional levels 0, 8, and 16 hours after AOM 
injection in the colon of young and old rats fed either AIN or CUR (mean ± SE, n= 5 
or 6/group). AIN is the group fed the AIN-93 control diet and CUR is the group fed 
the AIN-93 diet containing 0.6% curcumin. * represents significant differences (p < 
0.05) between AIN and CUR at each time point and each age group. # represents 
significant differences (p < 0.05) among different time points at each age and each 
diet group by ANOVA. There were no significant effects of diet or AOM treatment in 





6.3.4 Caspase-9 protein levels 
As shown in Figure 18, in the young, rats fed the curcumin diet had a higher 
ratio of active caspase-9 to procaspase-9 compared to rats fed the control diet in all 
times consequently showing a significant diet effect (p = 0.004).  The ratios of active 
caspase-9 to procaspase-9, which reflect the activity of caspase-9 were significantly 
increased 0 and 8 hours after AOM injection in young rats fed curcumin diet 
compared to rats fed the control diet (Fig. 18).  There were no significant differences 
between two diet groups in all time points in middle-aged or old rats (Fig. 18).   
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Figure 18. Effect of curcumin on the activity of caspase-9 in the colon of three 
different ages of rats, 0, 8, and 16 hours after AOM injection (mean ± SE, n=5 or 
6/group). (A) Proteins were separated by electrophoresis and blots were probed with 
caspase-9 antibody, lane 1-2; 0 hour, lane 3-4; 8 hour, lane 5-6; 16 hour in young rats. 
Bands of 45 kD and 35 kD corresponded to procaspase-9 and active caspase-9, 
respectively. (B) The ratio of active caspase-9 to procaspase-9 was calculated after the 
densitometry corresponding to the size of two proteins was quantified by Image J 
software. β-actin was used as a loading control and there was no difference in 
intensity of β-actin protein among samples (not shown). p values represent the overall 
effect of diet in each age group. * represents significant differences (p < 0.05) 




















































The hypothesis of this study was that the resistance of middle-aged rats to 
curcumin-induced apoptosis at the initiation of colon carcinogenesis contributes to the 
failure of curcumin to inhibit colonic ACF in this age group.  The results support this 
hypothesis as young and old rats fed the curcumin diet had higher levels of apoptosis 
compared to rats fed the control diet whereas middle-aged rats had similar levels of 
apoptosis in both diet groups.  Curcumin similarly affected cell proliferation 
assessed by PCNA immunohistochemical staining in all age groups and significantly 
reduced proliferation rate after AOM injection (Table 3).  This result support 
previous reports that the ability to enhance apoptosis or differentiation rather than 
suppress cell proliferation correlates with efficacy of chemopreventive agents (33, 153, 
199).   Therefore, induction of apoptosis by curcumin before and/or right after 
carcinogen treatment may be at least partially responsible for the differential 
chemopreventive activity of curcumin (Chapter 2). 
Apoptosis may be important in inhibition of not only initiation of cancer but 
also progression of initiated cancer (33, 198).  Volate et al. (202) recently reported 
that curcumin reduced the number of colonic ACF induced by AOM in young rats and 
that this chemopreventive activity of curcumin was related with the increase of 
apoptotic incidence.  This is in agreement with the finding in this study as young and 
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old rats fed curcumin had significantly higher basal levels of apoptosis.  At this time, 
no reports were found to explain what contributes to the higher apoptosis incidence by 
curcumin-fed untreated rats or what are the biological consequences of this 
observation.  However, higher incidence of apoptosis in the AOM-untreated colon 
may provide protection against endogenous carcinogens in the colon, which is 
continuously exposed to toxic substances.  Therefore, through induction of apoptosis, 
curcumin may suppress the initiation of cancer, the development of initiated cancer 
cells to preneoplastic lesions and/or the growth of ACF with small multiplicity to ACF 
with larger multiplicity. 
As described earlier (Section 1.6), activation of procaspase-9 is mediated by 
the mitochondria.  The increase of apoptosis in rats fed curcumin was significantly 
associated with higher active caspase-9 relative to procaspase-9 in young rats (Fig. 
18).  However, this relationship was not observed in old animals, suggesting 
potential involvement of other pathways.  It should be also noted that the ratio of 
active- to pro-caspase-9 did not change with time after AOM injection in all age 
groups.  AOM-induced apoptosis may not require activation of caspase-9 but may be 
mediated by a mitochondrial-independent pathway.  
The mechanism of resistance to curcumin-induced apoptosis in middle-aged 
rats is unclear.  Previously, it was reported that curcumin failed to induce apoptosis 
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in cells which highly express Hsp70 (203) or Bcl-2 (85).  In this study, changes in 
transcriptional levels of Hsp70 with time after AOM treatment were measured to find 
if Hsp70 expression modulates curcumin-induced apoptosis.  Hsp70 was 
transcriptionally induced 8 hours after AOM treatment in young rats, reaching levels 
statistically significant at 16 hours.  This result suggests that the failure in detection 
of induction of Hsp70 transcription following AOM treatment in the previous study 
(Chapter 4) may be because Hsp70 transcription was evaluated at a much later time 
point after AOM treatment.  However, the feeding of curcumin in young rats reduced 
the elevation of Hsp70 mRNA levels.  Therefore, curcumin may act to eliminate 
stress rather than enhance Hsp70 induction as initially hypothesized in Chapter 4.  
Methylated proteins may induce transcriptional activation of Hsp70 in the colon 
following AOM treatment.  Young rats fed curcumin showed increased apoptosis 
incidence after AOM treatment compared to rats fed control diet and this removal of 
damaged cells by apoptosis may result in the reduction of protein damage that would 
induce Hsp70 in the colon.  In middle and old rats, Hsp70 does not appear to be 
induced by AOM and transcriptional levels of Hsp70 were not affected by feeding of 
curcumin either.  The lack of induction of Hsp70 in older rats may be because the 
higher incidence of apoptosis after AOM treatment in middle and old compared to 
young animals effectively removed stressed cells or because older animals have 
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reduced ability to induce Hsp70 (161, 204).  
The study above investigating time course of apoptosis in three different ages 
of rats (Chapter 5), showed no changes in Bcl-2, Bcl-xL, and IAP-2 mRNA levels in 
the colon of middle-aged rats after AOM treatment.  This is in contrast to the 
decrease of expression of those genes in young and old rats.  Bcl-2, Bcl-xL, and 
IAP-2 are regulated by activity of NF-κB and responsible for the resistance to 
apoptosis induction (176).  Although protein levels of those genes should be 
confirmed and the apoptotic pathway curcumin induces identified, the lower 
expression of Bcl-2, Bcl-xL, and IAP-2 suggests a means of sensitizes young and old 
rats to curcumin-induced apoptosis.   
Apoptosis mainly occurred at the bottom of the colon crypts in rats treated 
with AOM in both the previous (Chapter 5) and the current study.  However, rats fed 
the curcumin diet had more apoptosis in the middle or upper areas of crypts compared 
to rats fed the control diet after AOM treatment.  The differential localization of 
apoptosis by diet may be due to the enhanced differentiation and migration of cells in 
the curcumin diet group as suggested by Fenton et al. (205).  Cell differentiation is 
an important characteristic that indicates maintenance of tissue function.  It should 
be also noted that aging seems to increase apoptosis in post-mitotic tissues and 
probably mitotic tissues as well, as demonstrated in our previous study (Chapter 5).  
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Therefore, increasing apoptosis without enhancing cell differentiation would not be 
desirable as it would cause loss of tissue structure and function, further contributing to 
aging.  It should be further confirmed if curcumin enhances cell differentiation.  In 
this study, apoptotic incidence was enhanced by curcumin at a later time point after 
AOM treatment in old compared to young rats (Fig. 16).  The mechanism of this 
delay of increase of apoptosis by curcumin in old rats is also unclear.   
A previous study (109) reported that basal levels of cell proliferation 
determined by bromodeoxyuridine (BrdU) incorporation were not different among 
different ages of male F344 rats in contrast to increased proliferation in the colonic 
epithelium in older rats in this study (Table 3).  Hirose et al. (166) reported that 
PCNA labeling index was not reduced 8 hours after AOM injection when actively 
proliferating cells in the colonic epithelium are expected to be rare as mitotic index 
was significantly suppressed and apoptosis was highly induced at this time point.  
They speculated that cells in not only S phase but also G1 and/or G2 phase may 
immunoreact for PCNA.  PCNA plays important role both in DNA synthesis and 
DNA excision repair.  Possible occurrence of DNA excision repair after AOM 
treatment was also suggested as another explanation of no suppression of DNA 
synthesis assessed by PCNA labeling index after AOM treatment (166).  Therefore, 
different techniques used to assess cell proliferation might give different results.  
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Another possibility was that cell proliferation may be evaluated in tissues from 
different locations of the colon.  Holt and Yeh (206) reported an increased 
proliferation rate and a wider proliferation zone in aged rats in the distal colon but no 
changes were found in the proximal colon when they employed the tritiated thymidine 
incorporation techniques to assess cell proliferation rate.  In present study, there were 
no differences in cell proliferation by age, AOM treatment, or diet in the middle colon.  
A previous study also suggested that differential sensitivity to AOM depending on 
location in the colon (206) .  AOM treatment causes damages predominantly to the 
distal colon and changes of cell proliferation and mitosis were more apparent in the 
distal colon following AOM single injection (206) .  Therefore, the distal colon 
might be more susceptible to carcinogens, age, and probably diet.   
In summary, this study supports the hypothesis that the resistance of 
curcumin-induced apoptosis in middle-aged rats during initiation of AOM-induced 
carcinogenesis contributes to the lack of inhibition of colonic ACF by curcumin in 
this age of animals.  Further study will be required to identify the apoptotic pathways 




Chapter 7. Conclusions and Future Study 
 
Aging is a potent factor driving cancer including colorectal cancer.  The 
incidence of colorectal cancer, one of leading neoplastic diseases in Western countries, 
is strongly related with dietary factors.  Many food components have been 
extensively studied in relation to the development and prevention of colon cancer.  
However, previous studies in preclinical models have exclusively used young animals.  
The age of animals has not been considered in evaluation of chemopreventive effect 
of dietary components.   
The hypothesis of this thesis was that aging may alter the cancer preventive 
activity of dietary components.  Curcumin is a compound in the spice turmeric, 
powdered rhizomes of Curcuma longa Linn. and a well-established colon 
chemopreventive agent in preclinical models using young animals.  This hypothesis 
was tested by evaluating the effect of age on the inhibition of colonic aberrant crypt 
foci (ACF), preneoplastic lesions of colon cancer, by dietary curcumin.  Curcumin 
effectively reduced the number of colonic ACF in young and old rats whereas no 
reduction of ACF was found in middle-aged rats.  This resistance of middle-aged 
animals to curcumin chemopreventive activity was confirmed in an ACF study with 
only middle-aged rats.  It is important to find potential mechanisms responsible for 
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the resistance of curcumin chemoprevention in middle-aged animals, as it is middle to 
older individuals who are targeted in human clinical trials.   
One consideration was that the age-related difference in curcumin absorption 
and metabolism might contribute to this finding.  However, age did not alter the 
biological activity of curcumin in the liver or serum, which likely reflects absorption 
and metabolism of curcumin in vivo.   
Next, arachidonic acid metabolism was explored as a potential mechanism 
responsible for the resistance of middle-aged rats to curcumin chemoprevention.  It 
has been strongly believed that inhibition of cyclooxygenase-2 (COX-2) is an 
important colonic chemopreventive mechanism as seen in many studies investigating 
the relationship of non-steroidal anti-inflammatory drugs (NSAIDs) with colon cancer 
risk.  However, in this study, curcumin, which is known to inhibit cyclooxygenase 
(COX) activity, increased rather than decreased transcriptional expression levels of 
COX-2 in the colon of both young and middle-aged rats after treatment of 
azoxymethane (AOM), a colon carcinogen in preclinical animal models.  Moreover, 
in young rats, the increase of COX-2 mRNA expression in the curcumin diet group 
consequently increased prostaglandin E2 levels which reflect COX activity in vivo.  
This unexpected result leads to a reexamination of previous literature investigating the 
relationship between colorectal cancer risk and the use of NSAIDs or colonic COX-2 
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expression.  First, it was not evident that COX-2 expression is elevated in the early 
stage of colon cancer.  It seems that COX-2 expression is enhanced during 
progression of carcinogenesis.  Secondly, COX-2 expression is physiologically 
required and has a compensatory role with COX-1 in maintaining prostaglandin levels 
for integrity of the gastrointestinal mucosa.  No reports were found in the literature 
describing how AOM acutely affects expression of COX isoforms.  
Interestingly, the acute time course study demonstrated that AOM did not 
affect the colonic mRNA levels of COX-2 but reduced colonic COX-1 mRNA 
expression in all age groups.  These results suggest that curcumin may increase 
COX-2 mRNA expression in response to reduced levels of COX-1 mRNA levels in 
the colon.  This finding may be physiologically important, as deleterious side effect 
of NSAIDs due to inhibition of both COX-1 and COX-2 has long been a concern with 
their use in chemoprevention.  
Apoptosis, programmed cell death, plays a critical role in removing damaged 
cells upon exposure to carcinogens.  Apoptosis might be a relevant mechanism to 
prevent initiation of colon cancer.  Moreover, deregulation of apoptosis seems to 
contribute to the aging process.  However, the means by which regulation of 
apoptosis contributes to aging in mitotic tissues is largely unknown although in post-
mitotic tissues, it was suggested that increased susceptibility to apoptotic stimuli in 
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older individuals may be responsible for tissue dysfunction and aging phenotype.  
Therefore, a time course study of the apoptotic incidence in the colon following AOM 
injections in the three age groups was conducted.  There were no significant age-
related differences in either basal levels of apoptosis or a peak time of apoptotic 
incidence after carcinogen treatment.  However, the peak apoptotic incidence was 
significantly higher in middle-aged and old rats compared to young rats.  Therefore, 
older animals were more susceptible to AOM-induced apoptosis.  One may have 
speculated that older animals would be more resistant to apoptosis compared to young 
animals, as cancer incidence increases with age, suggesting the aged are more 
susceptible to cancers.  In fact, fewer colonic ACF were observed in older rats.  The 
increased response of old animals to apoptotic stimuli might be beneficial in 
preventing cancer in the short term.  However, in the long term, high incidence of 
apoptosis might cause loss of constituent cells and an increase of cell proliferation, 
increasing the likelihood of fixation of the mutation.  If individuals susceptible to 
apoptosis are subjected to repeated exposure to carcinogens, this long-term effect of 
high incidence of apoptosis may be significant.  
Lastly, the effect of aging on curcumin-induced apoptosis in the colons of 
AOM-treated and untreated rats was investigated.  Curcumin increased both basal 
and AOM-induced apoptosis in young and old but not in middle-aged rats.  
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Therefore, induction of curcumin-induced apoptosis immediately after carcinogen 
treatment correlated with the observation of the differential chemopreventive effect of 
curcumin in different aged rats.   
Transcriptional induction of Hsp70 by AOM was investigated.  However, 
clear evidence that Hsp 70 had a regulatory role in induction of apoptosis by AOM 
and/or curcumin was not found.  The family of proteins Bcl-2, IAP, and Hsp are 
among proteins that have a regulatory role in the induction of apoptosis.  There are at 
least two apoptotic pathways and many different proteins that regulate apoptosis.    
The mitochondrial-dependent pathway appears to mediate the curcumin-induced 
apoptosis in young rats as caspase-9 was activated in young.  However, caspase-9 
was not activated by curcumin in old rats.  AOM did not affect the activation of 
caspase-9 either in any age group.  Therefore, a mitochondrial-independent pathway 
might be responsible for AOM-induced apoptosis and curcumin-induced apoptosis in 
old rats.   
In conclusion, the studies in this dissertation provide evidence that aging 
modulates colonic chemopreventive activity of curcumin.  This is the first report 
demonstrating the effect of aging in dietary chemoprevention.  This age-related 
difference in chemoprevention efficacy seems to be due to a differential response to 
curcumin in the induction of apoptosis in different aged rats.  Responsible pathways 
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and proteins in curcumin-induced apoptosis should be further investigated.  Also, 
further study is needed to confirm whether this phenomenon of age-related differences 
in response to dietary chemoprevention occurs in humans and may contribute to the 
lack of agreement between preclinical studies in young animals and clinical studies 
with adult humans.  The relationship of high susceptibility to apoptosis in older 





Appendix 1. Unscheduled Sacrifices in Study 1. 
Animal 
number 
Age Diet Date necropsied Reason 
17 Middle-  
aged 
CUR 11/31/01 Sacrifice delayed to make up time of delayed 
weight recovery following the first AOM 
injection. 
35 Old AIN 10/10/01 Early sacrifice for ethical reasons, deteriorating 
condition; Not included in incidence tables 
because no tissues were collected for 
histological evaluation except colon.  
27 Old CUR 10/30/01 Found dead; Not included in incidence tables 
because of moderate autolysis in all tissues. 
33 Old AIN 11/04/01 Early sacrifice for ethical reasons, deteriorating 
condition. 
31 Old AIN 11/31/01 Sacrifice delayed to make up time of delayed 
weight recovery following the first AOM 
injection. 
25 Old CUR 11/16/01 Early sacrifice for ethical reasons, 12 cm 
subcutaneous mass.  
40 Old CUR 11/29/01 Sacrifice delayed to make up time of delayed 
weight recovery following the first AOM 
injection. 
39 Old CUR 11/29/01 Sacrifice delayed to make up time of delayed 





Appendix 2. Incidence of animals in Study 1 with macroscopic changes observed at necropsy. 
Age group Young Middle-aged Old 
Diet group AIN CUR AIN CUR AIN CUR 
Tissue/ Macroscopic 
observation 
      
LUNG       
Mass, white, raised     1/8 (30)  
Consolidated, dark red     1/8 (275)  
       
HEART       
Small     1/8 (37)  
       
SPLEEN       
Mass, white, raised     2/8 
(30,332) 
 




       
KIDNEY       
Discoloration, green    1/6 (17) 1/8 (31) 1/8 (404) 
Enlarged, bilateral     1/8 (31) 1/8 (404) 
Surface, granular, rough     2/8 (275, 
332) 
 
       
LIVER       
Nodule, raised, medial 
lobe 
  1/6 (19) 1/6 (16)  3/8  
(34, 394, 
253) 




Cyst, clear     1/8 (332)  
Focus, white     1/8 (332)  







Cont.: Appendix 2.   
THYROID       
Enlarged     2/8 (31, 
37) 
 
Small     1/8 (37) 1/8 (332)  
Discolored, dark red     1/8 (31)  
       
ADRENAL GLAND       
Mass, dark gray     1/8 (38) 1/8 (404) 
       
STOMACH       
Area, depressed, 
glandular mucosa 
    1/8 (275) 1/8 (29) 
       
COLON       






1/8 (36) 2/8   
(32, 28) 
Percent affected 17% 50% 33% 50% 12.5% 25% 
Discoloration, red 1/6 (11)   1/6 (18)   
TESTICLES       






Kryptorchism, bilateral      1/8 (394) 
       
       
PITUITARY GLAND       
Enlarged   1/6 (24)   1/8 (394) 
Discolored, red   1/6 (24)  1/8 (31)  
       
SKIN       
Mass, firm, white gray, 
subcutaneous 




Cont.: Appendix 2.   
MUSCULATURE       
Discoloration, dark red, 
pelvic 
     1/8 (28) 
Discoloration, dark red, 
peri-ocular 
    1/8 (275)  
       
EYE       
Discolored, red    1/6 (16) 2/8 (275, 
332) 
 
       
THORACIC CAVITY       
Hemothorax     1/8 (332)  
       
GENERAL BODY 
CONDITION 
      
Thin     1/8 (332)  
       
Total 2 3 4 7 30 20 
All animals were necropsied 11/27-28/01 with the exception of animals assigned upper case numbers:        
2Necropsied 11/4/01, 3 Necropsied 11/16/01, 4 Necropsied 11/29/01, 5 Found dead 10/30/01 
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Appendix 3. Incidence of animals in Study 1 with severity of common pathological age associated 
changes.  
Age group Young Middle-aged Old 
Diet group AIN CUR AIN CUR AIN CUR 
LUNG       
Infiltrate 
lymphoplasmocytic 
6/6 5/6 5/6 6/6 6/6 8/8 














Microgranuloma 3/6 5/6 3/6 4/6 3/6 5/8 
Percent affected/   
Mean Severity 
50% /  
1.3 
83% /  
1.4 
50% /  
1.7 
67% /  
1.5 
50% /  
2.3 
63% /  
2.2 
       
HEART       
Chronic 
Cardiomyopathy (CCM) 
5/6 6/6 6/6 6/6 6/6 8/8 
Percent affected/   
Mean Severity 












       
AORTA / LG. VESSELS 
/ HEART VALVES 
      
Myxomatous 
degeneration 
3/6 6/6 5/6 5/6 4/6 7/8 
Percent affected/   
Mean Severity 




83% /  
1.8 
83% /  
2.0 
67% /  
1.8 
88% /  
1.4 
       
KIDNEY       
Chronic Progressive 
Nephropathy (CPN) 
6/6 6/6 6/6 6/6 6/6 8/8 

















Cont.: Appendix 3.  
LIVER       
Microgranuloma 0/6 1/6 0/6 2/6 2/6 3/6 
Percent affected/   
Mean Severity 
0% /    
0 
17% /   
1.0 
0% /    
0 
33% /   
1.0 
33% /  
1.0 




2/6 1/6 4/6 2/6 1/6 3/6 
Percent affected/   
Mean Severity 
33% /   
1.0 
17% /  
1.0 
67% /  
1.8 
33% /  
1.5 
17% /  
1.0 




1/6 0/6 1/6 2/6 5/6 3/8 
Percent affected/   
Mean Severity 
17% /  
1.0 
0% /    
0 
17% /  
2.0 
33% /  
1.0 
83% /  
2.0 
38% /  
1.7 
Hyperplasia, biliary 0/0 0/0 6/6 6/6 5/6 8/8 
















3/6 3/6 6/6 4/6 5/6 7/8 
Percent affected/   
Mean Severity 
50% /  
1.0 




67% /  
1.5 
83% /  
2.2 




6/6 6/6 6/6 6/6 6/6 8/8 














Hyperplasia, nodular 0/6 0/6 0/6 1/6 0/6 2/8 
Percent affected/   
Mean Severity 
0% /    
0 
0% /    
0 
0% /    
0 
17% /   
3.0 
0% /    
0 
25% /  
1.5 
Hyperplasia, diffuse 1/6 0/6 1/6 1/6 3/6 3/8 
Percent affected/   
Mean Severity 
17% /   
2.0 
0%/      
0 
17%  / 
2.0 
17% /  
2.0 
50% /  
2.3 




0/0 0/0 0/0 0/0 1/6 3/8 
Percent affected/   
Mean Severity 
0% /    
0 
0% /    
0 
0% /    
0 
0% /    
0 
17% /   
3.0 




0/0 0/0 0/0 0/0 2/6 3/8 
Percent affected/   
Mean Severity 
0% /    
0 
0% /    
0 
0% /    
0 
0% /    
0 
33% /   
2.0 




Cont.: Appendix 3.  
MESENTERIC LYMPH 
NODE 
      
Accumulation of 
macrophages 
2/6 2/6 6/6 4/6 4/6 7/8 








67% /  
1.8 
67% /  
2.8 
88% /  
2.9 
       
THYROID       
Hyperplasia, C-cell 4/6 1/6 3/6 1/6 5/6 4/8 
Percent affected/   
Mean Severity 
67% /  
1.5 
17% /  
1.0 
50% /  
1.7 
17% /  
1.0 
83% /  
1.6 
50% /  
2.5 
       
ADRENAL GLAND       
Vacuolation, Zona 
fasciculata 
0/6 0/6 0/6 2/6 2/6 3/8 
Percent affected/   
Mean Severity 
0% /    
0 
0% /    
0 
0% /    
0 
33% /   
1.5 
33% /  
1.0 
38% /  
2.0 
       
STOMACH       
Infiltrate 
lymphoplasmocytic 
0/6 4/6 0/6 2/6 1/6 4/8 
Percent affected/   
Mean Severity 
0% /    
0 
67% /  
1.3 
0% /    
0 
33% /  
1.0 
17% /  
1.0 
50% /  
1.3 
Dilation, glandular 0/6 1/6 2/6 3/6 6/6 5/8 
Percent affected/   
Mean Severity 
0% /    
0 
17% /   
1.0 
33% /  
1.5 




63% /  
2.2 
       
DUODENUM       
Infiltrate 
lymphoplasmocytic 
0/6 1/6 1/6 1/6 1/6 3/8 
Percent affected/   
Mean Severity 
0% /    
0 
17% /   
1.0 
17% /   
2.0 
17% /  
1.0 
17% /  
1.0 




3/6 1/6 2/6 0/6 1/6 0/8 
Percent affected/   
Mean Severity 
50% /  
2.7 
17% /  
2.0 
33% /  
1.5 
0% /    
0 
17% /  
3.0 





Cont.: Appendix 3.  
PANCREAS       
Atrophy, acinar cells 1/6 3/6 2/6 1/6 2/6 3/8 
Percent affected/   
Mean Severity 
17% /  
1.0 
50% /  
1.7 
33% /  
2.0 
17% /  
1.0 
33% /  
1.5 
38% /  
1.3 
       
JEJUNUM       
Vacuolation, villi, 
lamina propria 
1/6 1/6 2/6 1/6 0/6 1/8 
Percent affected/   
Mean Severity 
17% /  
1.0 










ILEUM       
Vacuolation, villi, 
lamina propria 
3/6 1/6 1/6 0/6 0/6 0/8 
Percent affected/   
Mean Severity 
50% /  
2.3 
17% /  
1.0 
17 % /   
0 
0% /    
0 
0% /    
0 
0% /    
0 
       
SMALL INTESTINES       
Vacuolation, epithelial, 
villi and lamina propria 
5/6 2/6 4/6 1/6 1/6 1/8 
Percent affected/   
Mean Severity 
83%/   
2 
33%/   
1.9 
68%/   
2 
17%/   
2 
17%/   
3 
12.5%/   
2 
       
COLON 6/6 6/6 6/6 6/6 6/6 7/8 
Crypt drop out       
















6/6 6/6 6/6 5/6 6/6 8/8 

















2/6 5/6 5/6 6/6 5/6 8/8 
Percent affected/   
Mean Severity 
33% /  
1.5 
83% /  
1.4 












Cont.: Appendix 3.  
TESTES       
Hyperplasia, interstitial 
cell 
2/6 0/6 5/6 5/6 6/6 6/8 
Percent affected/   
Mean Severity 
33% /  
1.0 
0% /    
0 
83% /  
1.6 




75% /  
2.7 
       
EPIDIDYMIS       
Vacuolation, epithelial, 
basophilic, cytoplasmic 
0/6 1/6 4/6 1/6 3/5 5/8 
Percent affected/   
Mean Severity 
0% /    
0 
17% /   
2.0 
67% /   
1.8 
17% /  
2.0 
60% /  
2.7 
63% /  
2.0 
       
PROSTRATE GLAND       
Inflammation 5/6 4/6 6/6 3/6 4/5 7/7 
Percent affected/   
Mean Severity 
83% /  
2.2 




50% /  
3.0 




Hyperplasia, epithelial 5/6 5/6 6/6 3/6 4/5 6/7 
Percent affected/   
Mean Severity 
83% /  
1.6 




50% /  
2.0 
80% /  
1.5 
86% /  
2.2 
       
SEMINAL VESICLE       
Hyperplasia, epithelial 5/6 2/6 2/6 2/6 3/5 4/7 
Percent affected/   
Mean Severity 
83% /  
2.0 
33% /  
1.5 
33% /  
2.0 
33% /  
2.0 
60% /  
2.3 
57% /  
2.5 
       
COAGULATING 
GLAND 
      
Hyperplasia, epithelial 4/6 4/6 4/6 3/6 3/5 4/7 
Percent affected/   
Mean Severity 
67% /  
1.5 
67% /  
2.0 
67% /  
1.8 
50% /  
1.3 
60% /  
2.3 
















      
Stomach      1/8 
Percent affected/   
Mean Severity 
     13% /  
2.0 
Pancreas   1/6    
Percent affected/Mean 
Severity 
  17% /  
3.0 
   
Testis     1/6  
Percent affected/Mean 
Severity 






Appendix 4. Incidence of animals in Study 1 with severity of small intestinal lamina propria 
vacuolation. 
Age group Young Middle-aged Old 
Diet group AIN CUR AIN CUR AIN CUR 
Small intestines       
Vacuolation, villi, 
lamina propria 
5/6 2/6 4/6 1/6 1/6 1/8 
Percent affected/   
Mean Severity 
83% /   
2 
33% /  
1.9 
68% /   
2 
17% /   
2 
17% /   
3 





Appendix 5. Incidence of animals in Study 1 with severity of hepatocellular hyperplasia 
(nodular and diffuse) and altered hepatocellular foci. 
Age group Young Middle-aged Old 
Diet group AIN CUR AIN CUR AIN CUR 
Liver       
Hyperplasia, 
hepatocellular 
1/6 0/6 1/6 1/6 3/6 5/8 
Percent affected/   
Mean Severity 
17% /   
2 
0% /    
0 
17% /   
2 
17% /   
3 
50% /   
2.3 




0/6 0/6 0/6 0/6 2/6 5/8 
Percent affected/   
Mean Severity 
0% /    
0 
0% /    
0 
0% /    
0 









Appendix 6. Incidence of animals in Study 1 with neoplastic lesions.  
Age group Young Middle-aged Old 
Diet group AIN CUR AIN CUR AIN CUR 
Lung       
Carcinoma 0/6 0/6 0/6 0/6 1/6 0/8 
Percent affected 0% 0% 0% 0% 17% 0% 
Hemo- lymphocytic system        
Lymphoma 0/6 0/6 0/6 0/6 1/6 0/8 
Percent affected 0% 0% 0% 0% 17% 0% 
Spleen       
Histiocytic Sarcoma 0/6 0/6 0/6 0/6 1/6 0/8 
Percent affected 0% 0% 0% 0% 17% 0% 
Thyroid Glands       
Adenoma 0/6 0/6 0/6 0/6 0/6 4/8 
Percent affected 0% 0% 0% 0% 0% 50% 
C-cell Carcinoma 0/6 0/6 0/6 0/6 2/6 0/8 
Percent affected 0% 0% 0% 0% 33% 0% 
Adrenal Glands       
Pheocromocytoma 0/6 0/6 0/6 0/6 1/6 0/8 
Percent affected 0% 0% 0% 0% 17% 0% 
Adenoma, Zona reticularis 0/6 0/6 0/6 0/6 1/6 0/8 
Percent affected 0% 0% 0% 0% 17% 0% 
Pancreas       
Adenoma, islet cell 0/6 0/6 0/6 0/6 1/6 0/8 
Percent affected 0% 0% 0% 0% 17% 0% 
Testes       
Adenoma, interstitial cell 0/6 0/6 0/6 0/6 5/6 6/8 
Percent affected 0% 0% 0% 0% 83% 75% 
Pituitary Gland       
Adenoma, pars distalis 0/6 0/6 1/6 0/6 2/6 1/8 
Percent affected 0% 0% 17% 0% 33% 12.5% 
Skin       
Fibroadenoma 0/6 0/6 0/6 0/6 1/6 0/8 
Percent affected 0% 0% 0% 0% 17% 0% 
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